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Resistance to chemotherapy is a major clinical problem in the treatment of cancer.
Doxorubicin is one of the most frequently used cytotoxic chemotherapeutic drugs,
especially for the treatment of breast tumours. Doxorubicin is a topoisomerase II inhibitor,
but also induces a variety of different types of damage in DNA. Emerging data has
suggested a potential role for DNA mismatch repair (MMR) in sensitivity of cells to
certain DNA damaging agents. The most clearly understood function of DNA mismatch
repair is the correction of mismatches occurring during DNA replication and
recombination. However, loss of MMR is now also associated with resistance in
mammalian cells to an ever increasing range of clinically important chemotherapy
agents.
In this present study we have examined the role of MMR in doxorubicin induced cell death
in yeast and human tumour cell lines. In addition, we have explored the clinical
relevance of loss of MMR protein expression in locally advanced breast cancer.
Doxorubicin sensitivity was examined in matched cell lines of defined MMR status
derived from A2780, a human ovarian cancer cell line. The cisplatin resistant derivative
A2780/CP70 has lost MMR activity due to loss of expression of the mismatch repair
protein MLH1 and is cross-resistant to doxorubicin. The hMLHl gene is located on
chromosome 3. Microcell-mediated transfer of a normal chromosome 3 into
A2780/CP70 restores MLH1 expression and significantly increases doxorubicin sensitivity,
as assessed by clonogenic assay (P<0.05). Whole chromosome transfer introduces multiple
genes and thus mechanisms not associated with MMR could be influencing doxorubicin
resistance in these chromosome transferrants. For instance, the gene encoding
topoisomerase II a on chromosome 3. However no alteration in topoisomerase II activity
was observed following chromosome 3 transfer into A2780/CP70.
In order to examine doxorubicin sensitivity in cells with only MMR genes inactivated, the
genetically tractable organism Saccaromyces cerevisiae was used. A significant 1.3-6 fold
increase (p<0.05) in clonogenic resistance was seen following doxorubicin exposure in
isogenic, haploid, strains with individual disruptions in the MMR genes MSH2,
MSH3, MSH6, and MLH1 compared to the wild type strain. Furthermore, re-
introduction of the MLH1 gene into the mlhl mutant, using a high copy yeast
expression vector, restored doxorubicin sensitivity to wild type levels. Together these
observations in yeast and human tumour cell lines are consistent with a role for MMR in
sensitivity to doxorubicin.
To determine if doxorubicin exposure frequently results in loss of MMR in human tumour
cell lines twenty cell lines were independently derived by repeated selection with
increasing doses of doxorubicin from A2780 and, the human breast cancer cell line, MCF7.
Resistance was confirmed by colony forming assay. All derived cell lines exhibited a
significant increase (P<0.05) in clonogenic resistance to 24-hour exposures of 50nM
(MCF7) and 15nM (A2780) doxorubicin. However, complete loss of expression of
hMSH2, hPMS2 or hMLHl was not seen on Western immunoblot or
immunohistochemistry and no loss of MMR was observed as defined by acquisition of
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microsatellite instability (MSI). This suggests that loss of MMR is not frequently observed
in these cell line models using these selection and assay conditions
In order to examine the potential clinical relevance of MMR protein expression in breast
cancer, we examined the expression of MLH1 by immunohistochemistry in 29 women
with locally advanced breast cancer before and after primary (neoadjuvant) chemotherapy.
MLH1 expression was correlated to disease free survival and clinical information was
obtained retrospectively from patient notes. Primary chemotherapy results in a significant
reduction in MLH1 expression as assessed by both intensity (p=0.02) and percentage
(p=0.01) cell staining. In addition, loss of MLH1 expression is strongly associated with
poor disease free survival for both percent (p=0.003) and intensity (p=0.016) of staining.
In multivariate analysis using statistically significant clinical features percentage staining
following chemotherapy is identified as an independent prognostic factor (p = 0.019). P53
expression, assessed by immunohistochemistry, was not significantly altered by primary
chemotherapy and did not predict disease free survival. There was no association between
p53 and MLH1 expression (p = 0.41).
In conclusion, we have demonstrated the clinical relevance of loss of MLH1 in locally
advanced breast carcinoma as an independent predictor of poor DFS. Large prospective
studies are now necessary to validate these clinical observations.
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1. INTRODUCTION AND AIMS
Why study drug resistance in malignancy?
Cancer is a vast medical problem. It is diagnosed in one in 250 men and one in
every 300 women each year in the UK (Souhami and Tobias, 1998). Relative
success has been achieved in terms of local control of disease using surgery and
radiotherapy. Whilst this is a worthwhile and important aim it has not greatly
improved prognosis. The most important cause of death remains visceral spread of
disease. Despite over 50 years experience in the treatment of malignancy with
chemotherapeutic agents the majority of patients who develop cancer at the
beginning of the 21st century will eventually die from their disease (Kramer and
Klausner,1997). As yet, we cannot determine the subgroups of people who will do
well or badly. Treatment failure is a major problem. Many tumours appear inherently
resistant to drug therapy, whilst others display initial sensitivity followed by
resistance often, not only to the initial agents, but to a broad range of anticancer
drugs. The study of how and why resistance to chemotherapy develops is essential
to our understanding of tumour biology and imperative if we are to improve the
outlook for cancer patients in the next century.
Anticancer drug resistance can be conceptualised into 3 general areas of study:
• drug delivery
• drug:target interactions
• post-target cellular responses.
This thesis focuses on one area of drug:target interaction the recognition of DNA
damage and the engagement of apoptosis.
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Several studies have suggested a role for DNA mismatch repair (MMR) deficiency
in the development of resistance to cisplatin and the monofunctioning alkylating
agents (Anthoney et al. 1996, Drummond et al. 1996, Fink et al. 1998 a and b, Karran
and Marinus, 1982). The anthracycline antibiotic doxorubicin is an important
antineoplastic agent which has a number of mechanisms of action including DNA
topoisomerase II inhibition, DNA intercalation and the generation of free radicals
(Doroshow, 1996). Cell lines selected for resistance to cisplatin and which have
lost MMR protein expression have been shown to be cross-resistant to doxorubicin.
Translation of laboratory findings into the clinic is the key to improving patient
prognosis in the future.
This thesis aims to:
• Explore the relationship between mismatch repair deficiency and resistance to
doxorubicin.
• Characterise DNA mismatch repair in independently derived doxorubicin resistant
cell lines.
• Assess the impact in vivo of chemotherapy on the expression of the mismatch
repair protein MLH1 in breast cancer.
• Assess the impact in vivo of chemotherapy on the expression of the tumour
suppressor gene product p53 and its association with the mismatch repair protein




The anthracycline antibiotic doxorubicin (also known as adriamycin) was discovered
over 30 years ago and remains one of the most widely used antineoplastic agents
in current clinical practice (Di Marco et al. 1969). It is active over a wide range of
doses and in a variety of administration schedules(Legha et al. 1982, Jones et al.
1987) Its broad anti-tumour activity and lack of antagonism with other
chemotherapeutic agents, makes it a valuable agent for use in drug combinations
(Bielack et al. 1996). Doxorubicin-containing combination chemotherapy protocols have
become standard therapy for cancers of the breast, bone and soft tissue sarcomas,
haematological malignancies and many childhood solid tumours (Doroshow, 1996).
In order to understand how mismatch repair could have a role in doxorubicin
induced cell death, it is first necessary to consider the intracellular interactions and
proposed mechanisms of action of doxorubicin.
1.1.2. Doxorubicin: chemistry and mode of cytotoxicity
Doxorubicin entry into the cell is by free diffusion of the unionized drug across
the cell membrane (Peterson and Trouet, 1978). Extracellular and intracellular pH
have a significant impact on doxorubicin uptake, as the drug becomes protonated
within the physiologic pH range. All nucleated cells have the ability to accumulate
the drug, due to DNA binding, rapid association with cell membranes and storage
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in several different intracellular compartments. The bulk of intracellular doxorubicin
is located within the nucleus (Doroshow, 1996).
There remains considerable controversy over the mechanism of action of the
anthracyclines and thus over the relative importance of various intracellular targets.
The major theories are discussed below.
1.1.2.1 Topoisomerase II
The most generally accepted mechanism of doxorubicin cytotoxicity involves the
interaction between doxorubicin and topoisomerase II. The DNA topoisomerases (I
and II) are involved in altering the tertiary structure of DNA to allow processes
such as transcription and replication to occur. The topoisomerases alter DNA
topology by generating breaks in the phosphodiester backbone which they stabilise
by the formation of transient covalent intermediates with the free ends of the DNA,
thus allowing passage of the strands through the gaps and the release of torsional
strain. Doxorubicin covalently binds to form a ternary drug-DNA-enzyme "cleavable
complex" halting the catalytic reaction prior to re-ligation and preventing
progression of the enzyme complexes involved in replication and transcription (Liu,
1989). Initially, intercalation leading to alterations in DNA topology was believed to
be the key factor in topoisomerase II inhibition. Subsequently, it was found that:
• Topoisomerase Il-associated DNA cleavage occurs at doxorubicin concentrations
below the dissociation constant for DNA intercalation (Potsmesil et al. 1983).
• The sugar and side chain of doxorubicin, responsible for minor groove binding,
is at least as important for drug activity as the planar intercalating moiety
(Capranico et al. 1997).
• Doxorubicin binds to and inhibits the purified topoisomerase II enzyme
(Doroshow, 1996).
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DNA topoisomerase poisons are invariably DNA-sequence specific. The consensus
sequence for highest doxorubicin affinity is 5'-TCA (Trist and Phillips, 1989). This
specificity appears to be determined by the drug enzyme interaction (Capranico et al.
1997). Could MMR be recognising the drug DNA enzyme complex thus leading to
cell death? Theoretical models for the MMR pathway are discussed in the next
section.
In comparison with other topoisomerase II inhibitors doxorubicin is known to exhibit
more cytotoxicity than expected per DNA break (Doroshow,1996). This means that
either doxorubicin associated DNA breaks are qualitatively different from those
produced by other anthracyclines or that other mechanisms of action are operating
in parallel. The presence of alternative mechanisms of action is supported by the
development of drug resistant cell lines, which fail to demonstrate drug DNA
enzyme complex formation (Bronner et al. 1994).
1.1.2.2 Additional potential mechanisms of cytotoxicity
Doxorubicin is known to bind to DNA. Several theories have been proposed as to
how DNA intercalation might mediate cell death, the best documented being the
inhibition of RNA and DNA polymerases (Zunino et al. 1975). Achievable intracellular
concentrations of doxorubicin in vivo, however, do not appear to cause intercalation
mediated inhibition of RNA or DNA synthesis (Siegfried et al. 1983). Doxorubicin
participates in redox cycling reactions that produce DNA damage including
crosslinks (Skladanowski and Konopa, 1994). MMR is known to recognise cross
links induced by cisplatin (Drummond et al. 1996). In addition, doxorubicin acts as a
DNA minor groove binder (Capranico et al.1997). Is MMR acting as a sensor of
doxorubicin induced DNA damage and cross-links?
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Cellular metabolism of doxorubicin results in the generation of semi qiunone free
radicals which may result in DNA damage and cell death (De Graffe et al. 1994).
This model is consistent with reports of cytotoxic potentiation by glutathione
depletion and of cytotoxic protection by endogenous free radical scavengers. These
studies, however, have largely been undertaken using MCF7 cell lines which are
characterised by unusually abundant activity of microsomal and pentose phosphate
pathway enzymes, thus providing an optimal substrate for free radical generation.
Studies using other cell lines have failed to implicate radical-mediated damage as
the predominant mechanism of doxorubicin action (Epstein review, 1990).
Doxorubicin has been shown to alter the fluidity of tumour cell plasma membranes
and cardiac mitochondria, bind to phospholipids and up-regulate epidermal growth
factor receptor expression (Benchekroun et al. 1993; Dickstein et al. 1993, Zuckier and
Tritton, 1983). At high concentrations doxorubicin can inhibit protein kinase C. At
lower, clinically relevant doses, cell line data has shown a two-fold increase in
cytosolic protein kinase C activity (Posada et al. 1989). A further study has suggested
that doxorubicin may be exerting a direct effect on transcription by downregulating
a sub-unit of RNA polymerase II (Fanciulli et al. 1996). These observations in vitro
are of uncertain significance in vivo .
Doxorubicin produces the morphological changes associated with apoptosis in a
range of cell lines (Doroshow, 1996). This apoptosis is modulated by the interplay
between the expression of the bcl-2 and p53 genes (Haldar et al. 1994).
In summary, the evidence suggests that DNA (rather than for example the cell
membrane) is the critical target for doxorubicin cytotoxicity. Speculation as to links
between MMR and doxorubicin induced cell death are purely hypothetical. There
22
have been no published studies looking at recognition of doxorubicin-induced
DNA lesions by components of the MMR system.
1.1.3. Doxorubicin: mechanisms of resistance
Many mechanisms have been proposed to account for the development of cellular
resistance to the effects of doxorubicin.
1.1.3.1. Enhanced drug efflux
The multi-drug resistance (MDR) phenotype is perhaps the most thoroughly
characterised mechanism of drug resistance (Kaye, 1988). Cell lines which display
this phenotype can be derived by selection, in vitro, with drugs including
doxorubicin. The MDR1 gene has been shown to code for a 170kDa transmembrane
glycoprotein called P-glycoprotein (Kartner et al. 1985) which is an energy dependent
unidirectional drug efflux pump (Willingham et al. 1986). The role of this protein in
experimental drug resistance has been well established. There is a good correlation
between the presence of this protein and a pattern of broad spectrum drug
resistance including to doxorubicin, the other anthracyclines and vinca alkaloids
(Endicott and Ling,1989). Transfer of the MDR1 gene into cell lines results in the
demonstration of the full drug resistant phenotype (Sugimoto and Tsuruo,1987).
Reversal of resistance in vitro can be achieved by a range of compounds that block
drug efflux by binding to P-glycoprotein (P-gp) (Kang and Perry, 1993; Hamada et al.
1987). Despite clear in vitro evidence the significance of p-glycoprotein expression
in tumours is less clear. Tumours such as kidney and pancreas, which display a
high level of expression of the gene, are often intrinsically resistant to a range of
anticancer drugs (Fojo et al. 1987). Examination of other tumour types, however,
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produces variable results. P-gp is rarely found at significant levels before or after
drug therapy in small cell carcinoma of the lung, but expression is clearly increased
in patients failing primary therapy for leukaemia, lymphoma or myeloma (Chabner
and Fojo, 1989). In breast cancer results have been conflicting (Trock et al. 1997),
although coexistent p53 and P-gp expression has been reported to be an
independent prognostic factor for short disease free survival (Honkoop et al. 1998).
Sequential samples taken from patients undergoing chemotherapy for breast cancer
have failed to demonstrate a change in the level of P-gp expression as a result of
exposure to chemotherapy (Linn et al. 1997).
P-glycoprotein is not the only cell membrane associated protein involved in the
development of multidrug resistance. MRP, so-called MDR related protein is another
ATP binding efflux pump implicated in the development of resistance to a range of
drugs including doxorubicin (Cole et al. 1992). In addition to acting as an efflux
pump from the cell this protein may also sequester drug in cytoplasmic vesicles
which are subsequently removed by exocytosis. Once again the clinical implication
of this protein remains unclear (Broxterman et al. 1995).
1.1.3.2. Intracellular drug metabolism
Glutathione (GSH) is one of the most prevalent intracellular thiols involved in
cellular detoxification. The formation of GSH-drug conjugates catalysed by a family
of Glutathione -S-transferase enzymes results in reduced toxicity and excretion of
the drug. Some evidence exists to suggest that doxorubicin-GSH conjugates maybe
excreted from the cell via an ATP dependent glutathione s-conjugate export pump
(Ishikawa et al. 1995). In vivo evidence, however is conflicting with reports of both
an association between glutathione S-transferase levels and acquired doxorubicin
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resistance (Kramer et al. 1988) and no role for this mechanism (Mestdagh et al. 1994).
Once again clinical significance remains unclear.
1.1.3.3. Topoisomerase II activity
The main target protein for doxorubicin is topoisomerase II. Doxorubicin resistance
in a number of cell lines (including the breast cancer cell line MCF7) has been
associated with reduced topoisomerase II activity and drug induced cleavage (de Jong
et al. 1990; Son et al. 1998). Furthermore, it is relatively common for tumour cells
selected with an anthracycline to exhibit altered topoisomerase II levels together
with increased p-glycoprotein expression (Friche et al. 1991). Mutation of the
topoisomerase II a gene has been demonstrated in cell lines selected with
etoposide. These are cross resistant to doxorubicin and drug sensitivity is partially
restored by transfection of the topoisomerase II a gene (Asano et al. 1996). The
importance of alterations in topoisomerase II levels has failed to be demonstrated
clinically. The activity of topoisomerase II in AML cells varies over more than a
20-fold range with significant cell to cell heterogeneity and no relationship between
enzyme levels and drug sensitivity (Kaufmann et al. 1994). In breast cancer, Linn et
al failed to demonstrate any predictive value for overall survival or response to
chemotherapy for topoisomerase II (Linn et al. 1997).
1.1.3.4 Signal transduction pathways
The role of signal transduction pathways in cell transformation has been extensively
studied. Cytotoxic agents disrupt these pathways and this may contribute to the
development of drug resistant clones (Brunton and Workman, 1993). Inhibition of
different isoforms of protein kinase C (PKC) results in alterations in doxorubicin
resistance, intracellular accumulation and p-glycoprotein expression (Ahn et al. 1996;
Budworth et al. 1997). Others have shown that the rate of efflux through p-
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glycoprotein can be controlled by phophorylation of specific amino acids within the
protein (Chin et al. 1992) suggesting a role for PKC in P-gp mediated drug
resistance.
There is evidence to suggest that transcriptional regulation of the MDR gene may
occur as a result of binding a complex consisting of activated c-fos and c-jun
(Volm, 1993; Ransone and Verma, 1990). Other oncogenes involved in signal
transduction pathways have also been implicated in drug resistant cell lines in vitro
(Kellen, 1994). Some studies have suggested that early expression of the oncogene
c-fos prepares cells for over-expression of other genes for example MDR3 that
contribute to the multidrug-resistant phenotype (Bhushan et al. 1996).
1.1.3.5. P53 and related pathways
The p53 tumour suppressor is involved in a number of key biological activities
including cell-cycle checkpoints apoptosis, senescence, maintenance of genomic
integrity and control of angiogenesis. Dysfunctional p53 correlates with decreased
sensitivity to a broad range of anticancer agents in vitro (Weinstein et al. 1997).
Multidrug resistant cell lines derived by exposure to doxorubicin have been shown
to have mutations within the p53 gene (Ogretmen and Safa, 1997). Furthermore, wild-
type p53 is necessary for induction of apoptosis in mouse thymocytes by
topoisomerase II inhibitors (Clarke et al. 1993). Lowe et al demonstrated the effect of
mutated p53, in vivo, on doxorubicin sensitivity in fibroblastic tumours developed in
mice (Lowe et al.1994). Some clinical studies have supported a role for mutant p53
in doxorubicin resistance (Aas et al, 1996) whilst others have failed to find a
correlation (Makris et al. 1997; Allred et al. 1993). Debate continues over the best way
to measure functional p53 and this will be discussed elsewhere in this thesis.
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In addition to apoptosis two other aspects of p53 biology may contribute to drug
resistance. First, mutant p53 can upregulate expression of P-gp thereby promoting
drug resistance in vitro (Chin et al. 1992). Clinical data, however, is conflicting with
reports of a correlation between mutant p53 and P-gp (Linn et al. 1997) and no association
(Schneider et al, 1994). Interestingly, co-existing p53 and P-gp expression has failed to
predict tumour responsiveness to chemotherapy in vivo. Secondly, p53 mutations relax
genomic integrity potentially leading to secondary mutations producing drug
resistance.
1.1.4. A role for defective DNA mismatch repair in doxorubicin
resistance?
Given the extensive literature examining mechanisms of resistance associated with
doxorubicin, is there any point in pursuing further potential mechanisms?
Doxorubicin is a very important clinical agent and with the development of new
drug delivery systems such as the introduction of liposomal doxorubicin and the
use of macromolecules such as PK1 (Duncan et al. 1988) it is likely to remain so.
Despite intensive research , as can be seen from the discussions above, clinically
significant factors in the development of resistance have remained elusive.
Furthermore, loss of mismatch repair is potentially a common mechanism of
resistance to a number of drugs which, given our poly-pharmacy approach to most
types of malignancy, requires further investigation. The limited amount of
experimental evidence for the involvement of MMR in doxorubicin sensitivity is
discussed at the beginning of Chapter 3.
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1.2. DNA MISMATCH REPAIR
1.2.1 Introduction
DNA mismatch repair (MMR) plays an important role in maintaining the integrity
of the genome by recognising and allowing repair of errors made during DNA
replication and recombination. In addition, increasing evidence suggests an
association between expression of MMR proteins and sensitivity to a range of
clinically important anticancer drugs including cisplatin/carboplatin, doxorubicin and
temozolomide (Aebi et al. 1997). Loss of MMR leads to reduced ability of cells to
engage drug induced apoptosis (Anthoney et al. 1996).
Mutations in MMR genes occurs in the cancer susceptibility syndrome hereditary
nonpolyposis colorectal carcinoma (HNPCC) which results in an increased incidence
of colorectal carcinoma as well as other tumours including adenocarcinomas of the
ovary, stomach and pancreas (Lynch, 1993). Mutations in the MMR genes MLH1,
MSH2, PMS2 and PMS1 have all been found in HNPCC with the vast majority of
mutations effecting MLH1 and MSH2 (Liu et al. 1996). An increased rate of mutation
occurs in simple repetitive base sequences (microsatellites) within cells taken from
HNPCC related tumours, so-called microsatellite instability (MSI) or MIN+ (Aaltonen
et al. 1993). The MIN+ phenotype is increasingly being observed in a variety of
sporadic tumour types including breast, ovary, pancreas and small cell lung
carcinomas (Paulson et al. 1996; Eshleman and Markowitz, 1995), suggesting that these
tumours are also MMR-defective (Liu et al, 1995). It should be stated that loss of
mismatch repair is only one cause of a mutator phentoype, other causes include: loss of
genes involved in DNA repair, replication or chromosomal segregation, for example
germ line p53 mutations in Li-fraumeni syndrome (Loeb, 1994); however, not all of these
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will give rise to an increased rate of frameshift mutations. It can also be envisaged that
other, as yet unidentified, mechanisms give rise to a higher mutation rate in the genome.
1.2.2. Mechanism of strand specific mismatch repair
The most clearly understood function of MMR is the post replicative recognition of
DNA polymerase insertion errors which have escaped proof-reading (Modrich, 1997).
The proposed model for post replication MMR is based on work with the DNA
adenine methylation-instructed MMR pathway of Escherichia coli (Modrich and
Lahue,1996). The MutS protein binds directly to mispaired nucleotides that result
from misincorporation errors. MutL protein is then recruited to form a recognition
complex. MutS recognises all single mispairs, except possibly C-C (Su et al. 1988).
The MutS:MutL complex then associates with another protein MutH. MutH is an
endonuclease which incises specifically at hemi-methylated GATC sequences within
the newly synthesised DNA. This allows discrimination between the strands and
incision to occur only on the daughter strand containing the mispaired bases. It is
this nick which directs DNA repair (Au et al. 1992). Following incision a single-
stranded DNA exonuclease (Exo I, Exo VII or the RecJ protein) removes the DNA
between the MutH incision site and up to 100 bases past the mismatch (Cooper et
al. 1993). A single stranded DNA binding protein, SSB and helicase II (UvrD)
proteins are also required during this process. After removal, DNA polymerase III
synthesizes the correct strand which is subsequently ligated into place.
MMR in eukaryotes, as in prokaryotes, appears to be bi-directional and strand
specific although the signal for strand-discrimination in vivo is unknown. Repair in
vitro (in both humans and yeast) can be directed to one strand by a nick in the
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Figure 1. Schematic diagram of eukaryotic mismatch repair.
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DNA substrate (Holmes et al. 1990). MutS and MutL homologues in mammalian cells
exist primarily as heterodimeric proteins (illustrated in figure 1.). MSH2 protein
associates with MSH3 and MSH6. These complexes are referred to as MutSa
(MSH2/MSH6) and MutS|3 (MSH2/MSH3). There appears to be some redundancy in
the system as both complexes recognise short insertion/deletion loops, but only
MutS<sfc(MSH2/MSH6) recognises base-base mismatches. MutSa and MutS(3 may act
in a complementary fashion differentially recognising insertion/deletion heterologies
depending on size and sequence context. Adenine nucleotide binding and hydrolysis
by MutSa has been suggested to act as a molecular switch that determines
downstream MMR events (Gradia et al. 1997). In this model MSH proteins survey
DNA in their ADP-bound form. When DNA mismatch is detected, it provokes
ADP->ATP exchange by the MSH subunits, which causes conformational change,
leading to the formation of a hydrolysis-independent sliding clamp in which the
MSH proteins encircle the DNA (Gradia et al. 1999). This ATP bound sliding clamp
is then able to move along the DNA strand and signal downstream effectors.
The MutL homologues also form hetero dimers. hMLHl forms a complex with
hPMS2 (yeast homologue sPMSl), hPMSl ( yeast homologue sMLH3) and the recently
discovered hMLH3 (Lipkin et al. 2000). So far, in humans, hMLHl/hPMS2 (MutLa),
and hMLHl/hMLH3 have been shown to participate in MMR. In yeast the
homologue of hPMSl sMLH3 in combination with sMLHl plays a role in the
repair of insertion/deletion mispairs by the MSH2/MSH3 pathway (Flores-Rozas and
Kolodner, 1998). Defects in hMLHl or hPMS2 lead to loss of mismatch correction
at, or prior to, the excision stage of repair. It has been proposed that MutS
homologues binding to mismatched DNA allows recruitment of MutL homologues
which then allows MMR to proceed. How this occurs is unclear. In the MutSa
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"sliding clamp" model MutL is proposed to act as an ATPase accelerating protein
which induces hydrolysis of ATP and release of the MSH2/MSH6 heterodimer from
the DNA thereby recycling the signalling switch (Fishel, 1999).
One of the important issues in MMR is the identification of other proteins required
for the process. Studies so far have implicated the exonucleases Exonuclease 1 and
FEN1 (RAD27 in yeast), DNA polymerases pol 8 and e, and DNA replication factors
RPA and RFC (Kolodner, 1996, Kolodner and Marsischky, 1999). In the yeast S.
cerevisiae, the replication factor, proliferating cell nuclear antigen (PCNA) has been
suggested to participate in MMR (Johnson et al. 1996; Kolodner and Marsischky, 1999).
PCNA is a required component of the eukaryotic replication apparatus forming a
homotrimeric sliding clamp around the helix and increasing the processivity of
DNA pol 8 and s. PCNA may be involved in assembling a complex of proteins at
the mispair (or elsewhere on the DNA) which is required for initiating MMR (Gu et
al. 1998). Proteins involved in strand discrimination and possibly mismatch incision
could be part of the complex. Alternatively PCNA may couple MMR to the
daughter strand directly as it is asymmetric and is loaded onto the DNA during
replication with a polarity (Kolodner and Marsischky, 1999). These theories remain
speculative.
The complexity of the emerging eukaryotic MMR system reflects roles beyond the
initially identified correction of errors arising during replication and recombination.
These roles may differ depending on the genetic background of the cell. MutL
homologues have been implicated in meiotic recombination in mice (Jiricny, 2000). It
has been shown that MSH2 and MSH2/MSH6 can bind types of DNA damage
normally thought to be repaired by other repair pathways such as nucleotide
excision repair (NER). Furthermore, MSH2 has been shown to interact, in yeast,
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with RAD1-RADIO and other NER proteins (Bertrand et al.1998) in addition to its
emerging role in the detection of environmental and drug induced DNA damage.
1.2.3. MMR and the development of drug resistance
Loss of expression of MMR proteins has been correlated with resistance to the
methylating agents procarbazine and temozolomide, the alkylating agent busulphan,
the platinum containing drugs cisplatin and carboplatin, the antimetabolite 6-
thioguanine, and the topoisomerase inhibitors etoposide and doxorubicin (Aebi et al.
1997; Drummond et al. 1996; Vaisman et al. 1998). Human colorectal and endometrial
adenocarcinoma cell lines which have lost expression of MLH1 and MSH2
respectively are resistant to a range of drugs. Chromosome transfer, leading to re-
expression of the MMR proteins, results in restoration of drug sensitivity (Aebi et al.
1997; Umar et al. 1997). Inactivation of MSH2 in the mouse causes "cellular resistance
to methylating agents and cisplatin (De Wind et al. 1995). How does loss of MMR
result in drug resistance? The answer is not clear. The observations above argue
against the theory that loss of MMR results in increased mutations at other genes
involved in drug resistance. They support a direct role for MMR proteins in
sensitivity to drug induced DNA damage. Several theories exist as to how loss of
MMR might lead to drug resistance and are discussed below.
Methylating agents form a variety of adducts in DNA including the cytotoxic lesion
06-methylguanine. The MMR system does not recognise this lesion directly. It does,
however, recognise the O6 -methylguanine-thymine mismatch that occurs during the
next cycle of DNA replication. Repair synthesis, which occurs in the newly
synthesized strand opposite 06-methylguanine, is doomed to failure because a
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thymine will once again be incorporated. The resulting futile cycles of repair are
proposed to lead to a double strand break that could trigger apoptosis (Fink et al.
1998a). This model predicts that loss of MMR would confer tolerance to the
methylating agents by virtue of the fact that the cell does not recognise the
mismatch and therefore would not attempt repair.
The above model is applicable to one type of DNA damage and certainly would
not be applicable to the lesions produced by doxorubicin. The discovery that loss of
MMR correlated with the acquisition of resistance to a range of DNA damaging
agents (and in particular to cisplatin) meant that a more inclusive model was
necessary. Several studies have suggested a link between MMR proteins and G2-M-
phase cell cycle arrest in response to a number of anti cancer drugs and radiation
(Brown et al. 1993; Davis et al. 1998). Davis et al have proposed that in a MMR
proficient environment the MMR system binds and recognises certain lesions
resulting in DNA breaks. These breaks produce a signal that results in G2-M-phase
cell cycle arrest and a loss of survival. Thus, in the absence of MMR these lesions
are not recognised, no strand breaks occur and G2-M-phase arrest is unable to be
induced (Davis et al. 1998).
Cellular proliferation, and hence, presumably DNA replication is required for
induction of apoptosis by cisplatin in vitro (Evans et al. 1994). Replicative bypass of
platinum induced DNA crosslinks occurs in MMR deficient drug resistant human
ovarian cells (Vaisman et al. 1998). The mechanisms leading to bypass are unknown.
In vitro DNA polymerase 5 and £ have been shown to bypass cisplatin induced
adducts although, so far, no role for MMR in this process has been demonstrated
(Hoffmann et al. 1995). Brown et al have proposed a model suggesting increased
recombination-dependent replicative bypass leading to drug resistance in yeast and
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ovarian cell lines (figure 2.). They have demonstrated a requirement of RAD52, a
protein known to be required for recombination, in drug resistance mediated by
MMR in S. cerevisiae. Furthermore, in ovarian tumour cells loss of MLH1
correlates with acquisition of cisplatin resistance and increased cisplatin-induced












Figure 2. Model of recombination-dependent bypass.
These models imply that DNA damage within the cell could be processed in
several different ways. First, the lesion may be repaired or may be cytotoxic and
induce immediate death Second, the lesion might persist and produce a signal
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during replication that triggers a cell death pathway, perhaps as a result of
replication stalling or arrest. Finally these lesions may be bypassed during
replication allowing survival. Loss of MMR may result in tolerance by reducing the
lethal signals being generated during replication by allowing increased bypass,
possibly recombination dependent and cell survival (Brown, 1999). In the case of
doxorubicin MMR could be recognising doxorubicin associated DNA cross links,
intercalated DNA or the topoisomerase II-drug-DNA complex .
How MMR-generated signals lead to apoptosis is unclear. P53 has been implicated as
part of one pathway linking MMR to apoptosis. It is a fundamental component of the
DNA-damage-inducible G1 cell cycle check point and in the maintenance of G2-M
arrest following DNA damage (Kastan et al. 1992; Agarwal et al. 1995). The nature of
the p53 response to DNA damage is governed, in part, by post-translational
modification of the protein. The relationship between p53 and MMR is not fully
understood. MutSa and MutLa-dependent activation of one or more protein kinases
that phosphorylate p53 have been observed in response to DNA methylation
damage in vitro. These result in phosphorylation of p53 at 2 serine residues. The
identity of the kinases are unknown. If p53 activation does play a role in the
response to methylation damage then alternate pathways must exist as p53 deficient
cells are still subject to methylator induced death (Duckett et al. 1999). Hickman et al
have demonstrated that MutSa is required for apoptosis induced by alkylating agents
and that this is independent of p53 (Hickman and Samson, 1999). In mouse intestine,
MSH2 dependent apoptosis in response to methylating agent damage is processed
via p53. If however, p53 is absent a delayed p53 independent apoptotic response is
engaged (Toft et al. 1999). P53 has been implicated in the apoptotic response to
cisplatin (Gallagher et al. 1997). The absence of MMR in human ovarian tumour
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models correlates with loss of p53 function and ability to undergo p53 dependent
apoptosis (Anthoney et al. 1996). Restoration of MMR, although it restores cisplatin
sensitivity, does not restore p53 function (Brown et al. 1998). Cisplatin, therefore,
appears to be involved in inducing at least two pro-apoptotic pathways one of
which involves p53 and the other signalled by the MMR pathway. This is
supported by observations in a colorectal tumour model, that lack of MMR
enhances the role of p53 in protecting the cells from cisplatin induced DNA
damage (Vikhanskaya et al. 1999).
The c-Abl nonreceptor tyrosine kinase and the c-Jun NH2 -terminal kinase are
activated during the injury response to cisplatin. In MMR deficient endometrial and
colorectal cell lines cisplatin activates JNK kinase less efficiently and the activation
of c-Abl kinase is absent. This suggests that these kinases are part of the signal
transduction pathway activated when cisplatin adducts are recognised by MMR
proteins (Nehme et al. 1997). P73 is a structural and functional homologue of p53
and also induces apoptosis. Accumulation of p73 occurs following cisplatin
exposure. This effect is dependent on a functional MMR system and c-Abl
activation (Gong et al. 1999;Yuan et al. 1999). Cisplatin appears to be involved in one
pro-apoptotic pathway involving p53 and a second involving p73 with only the
latter dependent on a functional MMR pathway. It is not known if p73 is involved
in inducing apoptosis in response to agents other than cisplatin. Furthermore, this
pathway has been suggested in only one cell line and needs further investigation in other
genetic backgrounds.
The inter-relationships between signalling pathways are likely to be complex and
their relative contributions to the response to DNA-damaging agents may depend on
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the cell type and agent examined. No published data exists examining MMR and
the response to doxorubicin induced damage.
1.2.4. Is loss of mismatch repair relevant in human tumours?
The presence of a microsatellite instability phenotype, a marker for loss of MMR,
has been shown to correlate with reduced survival and poor disease prognosis in
breast cancer (Paulson et al. 1996). Conversely, a MIN+ phenotype correlates with a
good prognosis in colon cancer (Bubb et al.1996; Elsaleh et al. 2000). These
differences may reflect the different impact of a mutator phenotype on tumour
progression versus drug sensitivity (this will be discussed more extensively in the
Discussion). A study in ovarian cancer has demonstrated an increase in the
proportion of MLH1 negative cells in tumour samples taken at second look
laparotomy following chemotherapy (Brown et al. 1997).
Given that MMR status appears to have implications both for prognosis and for




Breast cancer is the most common malignancy affecting women in the Western
world. It accounts for 20% of female cancer in the UK with 1 in 12 women
developing breast cancer during their lifetime. In Britain the age standardised
incidence and mortality are the highest in the world and the incidence is increasing
(Cancer Research Campaign, 1996). Despite radical surgery, more than 50% of
surgically treated patients eventually relapse. The introduction of adjuvant treatment
(endocrine, chemo- and radiotherapy) has resulted in a reduction in mortality, with
an 18-25% survival improvement at 10 year follow-up (Early Breast Cancer Trialists
Collaborative Group, 1992). Nevertheless, the survival figures continue to make grim
reading. For patients who develop distant metastases, the overall response rate to
chemotherapy is 40 to 60% with a median time to disease progression of between
4 and 6 months (Porrka et al. 1994). Response rates decline with subsequent lines of
treatment and all metastatic patients eventually die of their disease.
1.3.2. Doxorubicin in breast cancer
Doxorubicin is one of the most active agents in the treatment of breast cancer.
Response rates in randomised studies are in the range of 50% in previously
untreated patients with metastatic disease (Cancer: principles and practice of
Oncology. 4th Edition 1993 Devita, Hellman and Rosenburg). Similar results are
reported for combination regimens. Anthracyclines are also commonly included in
both adjuvant and neoadjuvant chemotherapy protocols.
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1.3.3. Prognostic factors in breast cancer
The identification of factors which predict the natural history of breast cancer and
tumour response to chemotherapy is vital if we are to improve the prognosis for
future patients. Currently, we are unable to fully identify sub groups of patients
who are going to do well or badly. This means that for example, 70% of patients
with lymph node negative disease will be cured by surgery alone, however we are
unable to identify the 30% whose prognosis would be improved by adjuvant
chemotherapy. This means that we are, undoubtedly, over treating some individuals
and under treating others. The isolation of markers that predict drug resistance
would allow us to select appropriate treatment regimens for individual patients and
potentially could aid in the development of new treatment strategies and/or agents.
Traditionally, clinical features have been used to predict the natural history of
breast cancer. The involvement of axillary lymph nodes by tumour remains the single
most important indicator of the risk of recurrence and death, with tumour size and
histological grade also of predictive value (Guidelines on the non-surgical
management of breast cancer, 1999). Currently, the only tumour markers
recommended for routine clinical use are oestrogen and progesterone receptor
measurements made on the primary tumour. The data has been insufficient to
recommend the routine use of proliferation indices, CA 15-3, CEA, P53 or cathepsin
D. Over expression of c-erbB-2 has been reported as an independent prognostic
factor for short disease free and overall survival, although data are conflicting
(American Society of Clinical Oncology, 1996). Mutation of the tumour suppressor
gene p53 is a frequent genetic change in breast cancer (Elledge and Allred, 1994)
and is generally viewed as an indicator of poor prognosis (Isola et al. 1992; Thor et
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al. 1992). Data for the MDR1 gene product P-glycoprotein (P-gp) are conflicting,
although co-existent p53 and P-gp expression has been reported to be an
independent prognostic factor for short disease free survival (Honkoop et al. 1998).
Factors consistently predicting tumour response to chemotherapy have proved
equally as elusive as those predicting survival. As discussed earlier in this chapter,
mutant P53 and p-glycoprotein expression have produced variable results in
predicting chemo-responsiveness in breast cancer. Other factors which have failed
to predict tumour response include the proliferation indices Ki67 and SPF, the
topoisomerases and MRP (Linn et al. 1997; Makris et al. 1997). Variable results
have been obtained for expression of the apoptosis inhibitor bcl2 and for over
expression of c-erbB-2 (Bonnetti et al. 1998; Makris et al. 1997; Rozan et al. 1998).
1.3.4. Microsatellite Instability in breast cancer
Microsatellite instability occurs in approximately 30% of sporadic breast carcinomas,
although reported rates vary (Wooster et al. 1994; Yee et al. 1994; Paulson et al.
1996). This is largely due to the difficulty in defining the MIN+ phenotype,
discussed in Chapter 6. Several studies have examined the association between
clinico-pathological parameters and the presence of an MIN+ phenotype. There
appears to be an association with features of poor clinical prognosis: including
increased mitotic rate, aneuploidy, larger tumour size, positive lymph node status
and higher pathological grade, most notably the histological subtype invasive lobular
carcinoma (De Marchis et al. 1997; Aldaz et al. 1995; Paulson et al. 1996). Furthermore,
Paulson et al have shown that the presence of an MIN+ phenotype is associated
with reduced disease free and overall survival. No published data exists on the
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impact of chemotherapy on the MIN+ phenotype or on the value of MIN+ as a
predictor of response to chemotherapy in breast cancer. The expression of MMR
proteins in sporadic breast cancer has not been evaluated. Further discussion on the






The following section lists routinely used materials. Those less frequently used are
described in the appropriate methods section
Chemicals
All chemicals were of the highest quality and were obtained from Gibco BRL,




(a P)dCTP used for labelling of DNA was obtained from Amersham International
pic,Little Chalfont, Bucks
Routine equipment which would be an integral part of any laboratory is not listed.
2.1.1. EQUIPMENT
Autoradiography film Kodak, Cambridge. UK
Fuji, Tokyo. Japan
Cell Counter Coulter Electronics. Luton Beds




Electrophoresis Tank IBI Ltd.
Flowgen.Lichfield. UK
Life Technologies. Paisley
Milliblot SDE Electroblotter Millipore, Watford, UK
Biorad.Hemelhempstead
Film Processor Kodak





Hybridisation Oven and Bottles
PCR Thermal Cycler
UV Crosslinker/imager





2.1.2. RESTRICTION ENDONUCLEASES AND OTHER ENZYMES
Hinfl (10-15 units/pl)
Proteinase K Gibco BRL
Taq polymerase Boehringer Mannheim
2.1.3. SIZE MARKERS
DNA
Hindlll digested phage X
lOObp DNA ladder
Protein




2.1.4. BUFFERS SOLUTIONS AND MEDIA
All solutions were made with double distilled water (ddH20) and stored at room
temperature except where indicated
Solutions for immunostaining




lml 100 vol. hydrogen peroxide + llitre of distilled ddH20
Sodium tricitrate buffer
2.94mg sodium tricitrate in 1 litre ddH20 pH to 6 with concentrated HC1
Blocking Solution
1 x Blotto




500mM Tris-HCl (pH 7.5)
500mM NaCl
lOmM EDTA

















(all stored at -20°C)













5ml lOOmM Na pyruvate
5ml 200mM L-glutamine
lml lMNaOH
50ml Foetal calf serum
2.5ml Penicillin/Streptomycin
8% Running gel
8ml running gel buffer
8.5ml 30%Acrylamide,0.8%bis-acrylamide(Severn Biotech, Kidderminster)
3.2ml 1% Polyacrylamide
12.3ml ddH20
120pl 10% Amonium persulphate
15pi Temed
4% Stacking gel







1.5M Tris-HCl, pH 8.9
4% SDS
Spacer gel buffer








PH to 6.4 with 2M KOH
Stored at 4°C.
Immediately prior to use protease inhibitors were added to the following final
concentrations:
0.2mM DTT (from mM stock kept at -20 °C)
lpM pepstatin
ImM PMSF



















Add 870mg to 11 ddt^O pH with NaOH to 5.5-6.0
Synthetic drop out yeast media
870mg/l Drop out mixture













0.25% w/v Bromophenol blue
0.25% w/v Xylene cyanol
Tris-EDTA buffer












0.25% xylene cyanol FF
TAE buffer


















100ml Membrane blocking reagent - prepare a 10% w/v solution of casein
hammarsten(BDH) in wash solution 2 by heating at 50-70 °C for 1 hour
Autoclave and store at -20°C.
Wash solution 1






pH adjusted to 7.5 with NaOH
2.1.5. CELL LINES
A2780
Human ovarian adenocarcinoma cell line derived from omental metastasis from an
untreated patient (Eva et al. 1982). Received from R.F. Ozols and T.C. Hamilton,
Fox Chase Cancer Centre, Philadelphia.
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A2780AD
Doxorubicin resistant derivative of A2780, isolated by repeated exposures to
doxorubicin (Rogan et al, 1984). This cell line is known to expresses high levels of p-
glycoprotein (Sugawara et al, 1988).
A2780/CP70
Cisplatin resistant derivative of A2780 selected for resistance by exposure to
increasing concentrations of cisplatin (Behrens et al, 1987).
A2780/CP70/chromosome 3
A2780/CP70 cell line transfected with chromosome 3 (Illand and Brown, 1998).
A2780/CP70/chromosome 2
A2780/CP70 cell line transfected with chromosome 2 (Illand and Brown, 1998).
MCF7
Human breast adenocarcinoma cell line established from the pleural effusion of an
untreated patient (Soule et al, 1973).
MCF7/AD
Doxorubicin resistant derivative of MCF7 isolated by selection against increasing
concentrations of drug (Sinah et al, 1986).
LoVo
Human colorectal adenocarcinoma cell line established from an untreated patient.
(Drewinko et al. 1979).
2.1.6. S. CEREVISIAE MUTANT STRAINS
Haploid isogenic strains were obtained from Dr. R Borts, Yeast Genetics, Institute
of Molecular Medicine, John Radcliffe Hospital, Oxford, UK. All strains are
derivatives of RHB2096 (Hunter and Borts 1997)






Table 1. Phenotypes of S. cerevisiae MMR mutant strains
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The strains were created by insertion of LEU2 into coding sequences of cloned
versions of the relevant genes. Plasmids were cut in sequences flanking the
disruptions and transformed into yeast using the LiAc transformation protocol.
Disruptants were selected on plates lacking leucine, screened for mutator
phenotype/uv sensitivity where possible and were confirmed by Southern analysis.
The kanmx disruption of Mlhl was made by PCR. Oligonucleotides homologous to
the 5' and 3' flanking region of Mlhl were made which also had sequences
homologous to the Kan gene. This was used to make a Kan containing plasmid to
get PCR product which had "tails" of homology to the flanking regions of Mlhl
surrounding the entire Kan gene. Transformation with this and selection for G418
resistance replaces the entire Mlhl reading frame for the Kan gene (Oliver, 1998).
Transfected strains of RBT311, were obtained from S. Durant, PhD student Drug
Resistance Group, Department of Medical Oncology, CRC Beatson Laboratories,
Glasgow.
2.1.7. ANTIBODIES
The following are a list of antibodies used for western immunoblotting and
immunocytochemistry
Antigen Antibody Isotype Company
hMLHl G168-15 Mouse monoclonal IgGi PharMingen
hMSH2 Ab-2 clone FE11 Mouse monoclonal IgG Calbiochem
hPMS2 Ab-1 clone 9 Mouse monoclonal IgGi Calbiochem
p53 DO-1 Mouse monoclonal
IgG2a
Oncogene science
Vinculin Vin-11-1 Mouse monoclonal IgGi Sigma
Table 2. Antibodies
Anti-mouse IgG horse radish peroxidase linked rabbit antibody (Amersham) and anti-
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mouse IgG fluorescein 5-isocyanate conjugated (FITC) goat antibody(sigma)
2.1.8. PCR PRIMERS
The primers used for repeat sequences, chromosomal location, locus heterozygosity




























































2.2.1. TISSUE CULTURE TECHNIQUES
2.2.1.1. General cell culture methods
Aseptic manipulations were performed using sterile glassware in a class II
microbiological safety cabinet with vertical airflow. Cell lines were grown and
maintained as monolayer cultures in supplemented RPMI (Rosswell Park
Memorial Institute) medium in the prescence of 5% CO2. A2780/CP70 cells
which had been transfected with chromosome 2 or 3 were grown in Hygromycin
B containing media (200u/ml). Cell stocks were made by freezing lxlO6 cells in
lml RPMI with 10% di-methyl sulphoxide (DMSO) at -70° C in 1ml
cryotubes(Nunc, UK). After 24 hours samples were transferred to liquid nitrogen.
All cell lines were routinely tested for mycoplasma infection every 4 weeks.
2.2.1.2. Selection of doxorubicin resistant cell lines
Ten doxorubicin resistant cell lines were selected by serial exposure to
increasing concentrations of doxorubicin from parental A2780 and MCF7 cell
lines. lxlO6 cells were grown in F75 tissue culture flasks (Bibby Sterlin,
Aberbargoed.UK) for 36 hours to attain log phase growth. A stock solution of
sterile doxorubicin was added to RPMI medium to obtain the desired final
concentration. Cells were exposed to doxorubicin containing medium for 24
hours at which point it was replaced by fresh medium. Cells were allowed to
grow for approximately 10 days with changes of medium as appropriate.
Surviving cells were then harvested by trypsinisation and lxlO6 cells were placed
in a new F75 flask for the next round of selection. The concentrations used in
the selection process were:
For A2780 lOnM, 20nM, 30nM, 60nM, 90nM, 150nM
For MCF7 lOnM, 20nM, 30nM, 60nM, 90nM, 150nM, 200nM, 300nM
2.2.1.3. Colony forming assay
1 x 103 cells were plated per 90mm diameter dish and after 24 hours doxorubicin
was added in fresh medium. The cells were exposed to the drug for 24 hours.
The doxorubicin containing medium was then removed and replaced by fresh medium.
The cells acting as controls had changes of fresh, drug free, medium in parallel with the
drug exposed cells. Colonies were grown for 10-14 days after doxorubicin exposure
and then stained with lx Geimsa stain for 10 minutes and rinsed with tap
water. Colonies greater than 200 cells were counted. 5 plates were set up at
each dose point per experiment. The experiments were repeated at least once, survival
fractions in this thesis are reported as a mean of at least 10 plates (1 x 104 cells).
2.2.2. YEAST CULTURE TECHNIQUES
2.2.2.1. Preparation of YPD medium
Difco peptone, yeast extract and agar (if required for solid medium) were
dissolved in ddfUO and the pH adjusted to 5.8. The solution was autoclaved
and allowed to cool to 55°C when 50ml of a filter sterilised 40% dextrose
solution was added.
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2.2.2.2. Yeast Clonogenic Assay
Cells were scraped from stocks stored at -70 °C. They were grown to saturation
in 10ml YPD medium for approximately 48 hours in a 30 °C incubator undergoing
constant agitation. Cells were counted using a haemocytometer (Weber, England)
and 2 x 107 cells were added to 1ml of YPD medium containing a range of
doxorubicin concentrations. These were incubated for 24 hours at 30 °C. 400 cells
were then plated out on solid YPD culture medium and incubated at 30 °C. The
surviving colonies were counted after 3 days and the surviving fraction calculated
relative to the no drug control.
2.2.2.3. ScMLHl transfected yeast
These strains were obtained from S Durant.
The MLH1 deficient strain of S. Cerevisiae was transfected with wild -type
scMlhl using low and high copy yeast expression vectors, pyxll2 and pyx212
(R and D Systems). Cells were grown in selective Yeast Drop Out Medium ( no
uracil).
2.2.3. GEL SEPARATION AND IMMUNODETECTION OF
PROTEINS
2.2.3.1. Extraction of protein
Cells, grown in monolayer culture, were washed with PBS, then lysed at 4°C
for 5 min using high salt lysis buffer supplemented with 1 x protease inhibitors.
Cell supernatant containing extracted proteins was collected by centrifugation of
lysate in cooled Eppendorf tubes at 4HC (21000g/15min) and then stored at -
70°C.
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2.2.3.2. Determination of protein concentration
Estimation of protein concentration was performed using Bio-Rad Protein assay
with standard curve constructed using Bovine serum albumin.
2.2.3.3. Sample preparation
75pg protein was mixed with 1/5 volume western loading dye and boiled for 3
min to facilitate protein denaturation.
2.2.3.4. Denaturing gel electrophoresis of protein
Protein samples and size markers were separated by SDS-polyacrylamide gel
electrophoresis on an 8% running gel after passing through a preliminary 4%
stacking gel, both suspended in 1 x tank buffer. Proteins were electrophoresed at
200V/40mA until the dye front had migrated through the gel.
2.2.3.5. Western transfer of protein
Electroblotting was performed using a semi-dry electroblotter. Immobilin-P
membrane (Millipore, Bedford,MA) was immersed in methanol and then transfer
buffer. Six sheets of 3mm Whatman filter paper were sandwiched adjacent to
the anode and cathode with the membrane and gel layered in between. Transfer
took place over 1 hour at 200mA. To assess the evenness of protein transfer the
gel was subsequently stained in Coomassie stain (0.2% Coomassie Brilliant blue
R250 in a 50:50:7 v/v ratio of methanol:H20:glacial acetic acid) for 4 hr, then
destained using 25:68:7 v/v ratio of methanol:H20:glacial acetic acid overnight.
2.2.3.6. Immunological detection of protein
Membranes were incubated with blocking solution at 4°C for 4hr, probed
overnight in the same buffer with primary antibody and washed with 0.1%Tween-
20 in PBS. Blots were incubated in blocking solution with anti-mouse IgG HRP-
linked rabbit antibody, then washed again in 0.1%Tween-20 in PBS, after which
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bound complexes were visualised by enhanced chemiluminescence (Boehringer
Mannheim). Membranes were exposed to X-ray film and these were developed to
allow bound complexes to be visualised.
2.2.4. TOPOISOMERASE II ASSAY
2.2.4.1. Crude nuclear extraction
Subconfluent flasks of cells were washed with 10ml of ice cold PBS and cells
scraped off the base of the flask using a disposable cell scraper. This solution
was centrifuged at 500g for 10 minutes. The resulting cell pellet was
resuspended in 200pl of nucleus buffer in a 1.5ml eppendorf and freeze thawed
twice in a dry ice/ethanol bath. 3.5M NaCl was added to give a final
concentration of 0.35M NaCl. The cell solution was vortexed briefly and
incubated on ice for 1 hour with mixing taking place after 30 minutes. Cells were
then spun at 21000g for 20 mins at 4°C. Protein estimation was performed using
a Bio-Rad protein assay as described earlier. Nuclear extract was stored at -70°C.
2.2.4.2. Topoisomerase II Assay
This assay was performed according to the manufacturer's instructions
(TopoGEN Inc., Ohio). Activity of topoisomerase II is observed through the
enzyme's ability to decatenate kinetoplast DNA (kDNA). A known amount of
nuclear extract was incubated with water, 10 x reaction buffer and kDNA at 37
°C for 20 minutes. Reactions were terminated by placing samples on ice and
adding 1/5 volume of stop buffer/loading dye. Activity was resolved in 1%
agarose/TBE gels containing 0.05% ethidium bromide. TBE was used as running
buffer and gels were run at 150V/40mA for 45 minutes. Markers kDNA, linear
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kDNA and Topo II decatenated kDNA were run on each gel. Electrophoresed
DNA was visualised using a UV transilluminator and a record of the gel was
made using a digital imaging system.
2.2.5. DNA EXTRACTION
Genomic DNA was extracted from monolayer cultures using the Nucleon I DNA
extraction kit (Scotlab) following manufacturers protocol. DNA concentration
were determined by Hoechst 33258 staining and spectrophotometric quantitation
using standard curve human placental DNA.
2.2.6. AMPLIFICATION AND DETECTION OF DNA
2.2.6.1. Standard PCR
All PCR manipulations were carried out using dedicated micro-pipettes, aerosol
resistant tips and plasticware that had been sterilised by brief exposure to UV
irradiation. Water and other non-DNA containing reagents were also exposed to
UV irradiation to reduce contamination of samples with extraneous DNA. PCR
was carried out in a total reaction volume of 50pl in 0.5ml Eppendorf tubes
(Nunc.) 2pl of sample (50 to lOOng DNA) was added to 2pl of each primer
together with a master mix detailed below:






Thermal cycler parameters were individualised for each primer template
combination. Annealing temperatures were obtained, either from A Anthoney
(PhD thesis), G Hirst (personal communication) or were calculated using:
Annealing temp = 2x(A + T) + 4x(G + C)
Where G,C,A,T are the number of each nucleotides in the primer. Standard
melting and extension temperatures of 94 °C and 72 °C were used in each
reaction unless otherwise stated. The number of cycles of amplification was
generally 35. A technique of "Touchdown" PCR was used for reactions
involving microsatellite repeats(Don et al, 1991).
2.2.6.2. Agarose gel electrophoresis
To check for a successful PCR, samples were run on a 1% TBE agarose
minigel containing 0.05% ethidium bromide with lOObp DNA markers. Bands
were detected using a UV transilluminator.
2.2.6.3. Polyacrylamide gel electrophoresis
Following successful PCR denaturing polyacrylamide gels were used to resolve
individual microsatellite repeats. Gels were cast between pre-cleaned glass plates
one of which was coated with a silicon solution (Repelcote,Sigma. UK). The
glass plates were sealed to form a mould using adhesive tape and 30%
Acrylamide/0.85% bis-Acrylamide/7M Urea (Easigel) pre mixed solution was used




Wells were formed using a comb and the gel allowed to set for 1 hour.
Following this the combs were removed and the wells cleared of unpolymerised
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polyacrylamide and urea using 1 x TBE buffer. The gel was pre run for 1 hour
at 35mA/1800V. Samples were prepared for loading by adding 5pi of
fromamide loading dye to 7pi PCR product and placing in a water bath at 92°C
for 5 minutes. The reaction was terminated by placing the samples on ice. 8pl
of sample was loaded per well and the gel was run at 35mA/1800V in 1 x TBE
buffer until the xylene cyanol FF band was at the bottom of the gel
(approximately 2-3 hours). The gel was blotted onto a sheet of 3mm
chromatography paper (Whatmann,UK) and dried under vacuum at 80°C for 1
hour. It was then exposed to X-Ray film in a cassette with tungstate intensifying
screens at room temperature.
2.2.7. DNA FINGERPRINTING
DNA fingerprinting was carried out using protocols supplied by the European
Collection of Animal Cell Cultures, Centre for Applied Microbiology and
Research, Porton Down, Salisbury.
2.2.7.1. Isolation of genomic DNA
DNA was extracted using a salt-chloroform method from approximately 107
cells as described by Mullenbach et al (Mullenbach et al. 1989). DNA concentration
was determined as described earlier .
2.2.7.2. Restriction enzyme digestion of DNA
The DNA sample (equivalent to 40pg DNA) was added to 40pl xlO enzyme
buffer in a 1.5ml microfuge tube and the volume made up to 390pl with sterile
water. lOpl Hinfl (100-150 units) was added and mixed gently by vortex
followed by pulse centrifugation to draw all the reaction mixture to the bottom
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of the tube. This was placed in a water bath at 37°C for 4 hours, mixing every
hour. The reaction was terminated by the addition of lOpl 0.5M EDTA, 50pl 5
M NaCl and 1 ml ethanol, mixed well and cooled at -20°C overnight. The
samples were centrifuged 15000g at 4°C for 20 minutes by microcentifuge. The
supernatant was removed and the pellet washed with 500pl ice cold ethanol.
The sample was centrifuged at 15000g at 4°C for 2 minutes, the excess ethanol
removed and the pellet was air dried. The resulting DNA pellet was dissolved in
40pi TE buffer.
2.2.7.3. Agarose gel electrophoresis
0.8% TAE agarose gel containing 0.05% ethidium bromide was prepared, lpl of
digested DNA sample and lpl DNA loading buffer were mixed and loaded onto
the gel together with DNA size markers. The gel was visualised using the uv
transilluminator.
2.2.7.4. Southern blotting
The remaining DNA samples (39ig) were mixed with lOpl of DNA loading
buffer and run on a 0.8% TAE agarose gel. Approximately lOpg of DNA was
loaded into each lane and the gel was run at 20V over 18 hours. The resulting
DNA fragments were transferred to a nylon filter (Hybond N) by Southern
blotting.
2.2.7.5. Hybridisation of the DNA fragments with a NICE™ labelled probe.
Nylon support mesh was cut to the appropriate size to separate the nylon filter
membranes. The mesh and membranes were rolled and placed in a pre-warmed
hybridisation bottle. 30ml of 1 x SCC, pre-warmed to 50°C, was added to the
bottle for 5 minutes and then replaced by 30mls of, pre-warmed, pre-hybridisation
buffer. This was left for 20 minutes at 50 °C on a rotisserie. 10 pi of Non-
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Isotopic Chemiluminescent Enhanced (NICE™, ICI Cellmark Diagnostics) multi-
locus probe (33.15) was added to 16pl hybridisation buffer. The pre-hybridisation
buffer was removed, the above solution added and the bottle placed in the
hybridisation oven for 20 minutes at 50°C. The solution was removed and
100ml of pre-warmed wash solution 1 was added to the hybridisation bottle for
10 minutes at 50°C. The membranes were then transferred to a plastic box
containing 500ml of wash solution 1 and agitated for 10 minutes. 2 x washes in
500ml of wash solution 2 for 5 minutes at room temperature followed. Each
membrane was transferred to a glass plate and transferred to a fume cabinet
where 3-4mls of Lumi-Phos™ 530 (BDH) was added and spread out using a
glass pipette. Each membrane was then sandwiched between two transparent
acetate sheets and a ruler used to squeeze out any excess fluid. The membrane
acetate sandwich was placed against an X-ray sensitive film in a lightproof
cassette. This cassette was then placed in an incubator at 37°C for
approximately 6 hours (the chemiluminescence continues for up to 5 days).
2.2.7.6. Dehybridisation
NICE™ probes can be removed from the membranes by agitating them for 15
minutes in 0.1% SDS at 80°C followed by a rinse in 1 x SSC. The membranes can
then be stored.
2.2.8. IMMUNOCYTOCHEMISTRY
2.2.8.1. Immunohistochemistry of cultured cells
4 x 104 cells in 400pl of RPMI medium were added to each well of an 8 well
chamber slide (Nunc, Naperville, II. USA) and grown for 48 hours. The medium
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was removed and the cells washed with PBS. The plastic gasket was removed, the
slide dried in air and then, if not required, stored at -70°C wrapped in parafilm.
Dried slides were fixed in methanol at -20°C for 20 minutes and then air dried
for 40 minutes. Normal horse serum, diluted 1:10 with 0.1% BSA in PBS, was
added to the cells as a blocking agent and left for 20 minutes at room
temperature in a humid atmosphere. Excess liquid was removed and 50ptl
primary antibody diluted in 0.1% BSA in PBS, was added for 2 hours. Slides
were then immersed in 0.1% Tween-20 in PBS for 2 x 10 minutes before
incubation for 30 minutes with the secondary antibody. 50pl of the secondary
antibody (2.4pl anti-mouse-FITC plus 397.6pl PBS/BSA) was added per well and
followed by two further 10 minute washes in 0.1%PBS. The slides were then
mounted using Vectashield (Vector Labs, Burlingham. Ca. USA) and the edges
of the coverslip sealed with nail varnish. Slides were visualised and the image
stored using confocal microscopy.
2.2.8.2. Immunohistochemistry of paraffin embedded breast tissue
Immunohistochemistry was performed on histology sections taken from tru-cut
biopsy and mastectomy specimens. All samples were formalin fixed and paraffin
embedded. Mouse monoclonal antibodies G168-15 (1 in 100 dilution, PharMingen)
and DO-1 (1 in 200 dilution, Oncogene Science) were used to detect hMLHl
and mutant p53 respectively using a peroxidase labelled streptavidin-biotin
technique. Slides were deparaffinized in histoclear then rehydrated through graded
alcohols and water. Removal of endogenous peroxidase activity was achieved by
incubation in 0.1% hydrogen peroxide for 20 minutes. Sections were immersed
in lOmM sodium tricitrate buffer pH6 and subject to heat-induced antigen
retrieval by microwaving for 15 minutes then allowed to cool for 20 minutes.
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The tissue section was isolated using a PAP-pen. agent The commercially
available Vectastain® Elite ABC Kit (Vector labs, Peterborough, UK) was used to
detect the antigen. Slides were placed in a humid atmosphere and Normal Horse
serum (Vectastain® Yellow 3 drops in lOmls PBS) used as a blocking agent.
This was left for 20 minutes, the excess liquid removed and the primary
antibody added for 30 minutes. The slides were immersed in PBS for 5 minutes.
They were returned to the humid box and biotinylated anti-mouse IgG
(Vectastain® Blue 1 drop + 3 drops yellow in lOmls PBS) added for 30
minutes. ABC reagent (Vectastain® Grey 2 drops of A and B in 5mls PBS) was
made while the slides were washed in PBS for a further 5 minutes. The slides
were returned to the humid box and ABC was added to the slides for 30 minutes.
The PBS wash was repeated. The slides were returned to the humid box and each
tissue section was covered with 2-3 drops (100-200pl) of DAB diaminobenzidine
tetrahydrochloride for 10 minutes. The PBS wash was repeated. Sections were then
lightly counterstained with haematoxylin, dehydrated, placed in histoclear and a
coverslip was placed on each slide. Internal controls were obtained for each slide
by omitting the primary antibody. External controls included: for MLH1 A2780
cells (positive control for MLH1 and negative control for p53) and A2780/CP70
(negative control for MLH1 and positive control for p53). Two slides per patient
sample were immunostained in separate runs. Both scoring and immunostaining
were blinded to clinical outcome. Slides were scored by light microscopy by a
consultant pathologist. A score of 0 to 3 for stain intensity was assigned: No
staining = 0, weakly positive = 1, positive = 2, strong positive = 3. Percentage
staining was assessed by: 0 = 0-5%, 1 = 5-20%, 2 = 20-80%, 3= 80-100% and the
2 scores combined to give a potential maximum score of 6 (the IHC score).
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2.2.9. STATISTICAL METHODS
For statistical analysis of the patient samples involved in immunohistochemistry
variables taken into account included ER status, age, menopausal status, size,
grade and response to chemotherapy. All information was obtained retrospectively
from patient records. The within patient comparison of MLH1 and p53 scores
pre- and post chemotherapy was assessed using Wilcoxon signed rank sum test.
The examination of an association between p53 and MLH1 score was made
using Spearman's rank correlation coefficient. The univariate examination of the
association between disease free survival and p53, MLH1 and clinical factors
were made using the Cox regression analysis. The likelihood ratio P-value is
quoted. The multivariate analysis of factors associated with disease free survival
was also conducted using Cox (multiple) regression techniques and a forward
selection procedure ( P to enter = 0.05, P to remove = 0.10). Disease free survival
was taken from the time of commencing chemotherapy to relapse.
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CHAPTER 3
DOXORUBICIN RESISTANCE IN TWO MISMATCH




The development of drug resistance is a major clinical problem in the fight
against cancer. The identification of common pathways of drug resistance has a
key role to play in enabling us to plan therapeutic strategies and design new
approaches to cancer treatment. The circumstantial evidence for an association
between loss of MLH1 expression and doxorubicin resistance at the start of this
study included:
1. Enrichment of MLH1 deficient colonic tumour cells following exposure to
doxorubicin (Fink et al. 1998a.).
2. Cross-resistance to doxorubicin in, in vitro derived, cisplatin resistant ovarian
tumour cell lines which has lost MMR activity due to complete loss of
MLH1 expression (A Anthoney, personal communication) .
3. One, in vitro derived, doxorubicin resistant human ovarian tumour cell line
which has lost MMR activity due to complete loss of MLH1 expression. This
cell line exhibits cross-resistance to cisplatin (Drummond et al. 1996).
How loss of MMR could lead to drug resistance is not understood. It is,
however, important to establish if these findings represent direct involvement of
MMR proteins in sensitivity to DNA damage or if loss of MMR results in
increased mutation at other genes involved in drug resistance. This chapter
examines 2 cell lines known to be resistant to doxorubicin and to have lost
functional MMR activity in order to begin to address this issue.
The human breast cancer cell line MCF7 has functional MMR activity and
expresses all mismatch repair proteins. The clonal doxorubicin resistant derivative
MCF7AD is known to display microsatellite instability at 6 out of 13 loci
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examined, suggesting loss of mismatch repair activity (Anthoney et al. 1996).
MCF7AD had not been generated or characterised within our laboratory. It was
necessary to establish the authenticity of the cell line and confirm that it was
indeed derived from MCF7 before investigating it further.
A2780/CP70 a clonal derivative of the human ovarian adenocarcinoma cell line
A2780 isolated by in vitro selection for cisplatin resistance, demonstrates cross-
resistance to doxorubicin (Drummond et al. 1996). Furthermore, this cell-line has
lost expression of the MMR proteins MLH1 and PMS2 and exhibits MSI at 7
out of 11 loci examined. The parental A2780 cell line has intact mismatch
repair activity (Drummond et al. 1996; Anthoney et al. 1996). The gene encoding
for MLH1 is located on chromosome 3 (Bronner et al. 1994). Microcell mediated
transfer of chromosome 3 into A2780/CP70 results in re-expression of MLH1
(Illand and Brown,1998). If doxorubicin sensitivity could be restored by
chromosome 3 transfer this would suggest that MLH1 has a direct role to play
in the development of resistance to doxorubicin. A2780/CP70 cells containing
chromosome 3 were used as single MLH1 gene transfer had proved technically
difficult to achieve. The disadvantages of whole chromosome transfer include the
potential introduction of other genes involved in drug resistance. Topoisomerase
II is known to be a target protein for doxorubicin and to be associated with
doxorubicin resistance (Epstein, 1990). The gene for topoisomerase II |3 is located
on chromosome 3. To ensure that any observed restoration of doxorubicin
sensitivity was due to MLH1 expression topoisomerase II enzyme activity and
expressed protein levels were compared between cell lines.
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3.2 Aims of this chapter:
• To confirm the derivation of the doxorubicin resistant derivative MCF7AD
from MCF7.
• To determine if loss of MLH1 plays a direct role in sensitivity to
doxorubicin by comparing doxorubicin sensitivities between the cell lines
A2780, A2780/CP70 and A2780/CP70chr3.
• To assess the impact on topoisomerase II activity of chromosome 3 transfer
into A2780/CP70.
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3.2. DNA fingerprinting of MCF7 and MCF7AD human
breast cancer cell lines.
The genome of each individual has a unique set of repeated DNA sequences.
These can be identified in a wide range of species by Southern analysis of Hinf
I restriction enzyme digests of genomic DNA using the DNA probe 33.15
discovered by Alec Jeffreys. Visualisation of the unique pattern of sequences
provides a DNA fingerprint (Jeffreys et al. 1985 a and b). The DNA fingerprint
pattern of MCF7AD was compared to that obtained from parental MCF7
according to protocols obtained from the European Collection of Animal Cell
Cultures and described in Materials and Methods. Southern analysis of Hinfl
restriction enzyme digests of genomic DNA using the multi locus DNA probe
33.15 was used as this combination gives the most reliable differentiation of
human minisatellite polymorphisms (Jeffreys et al. 1985b; Stacey et al. 1991).
Figure 3. shows that the MCF7AD cell line within the laboratory was not
derived from parental MCF7. The Southern blot of the hinfl digest clearly
demonstrating different bands in each cell line as indicated by the arrows. This
implies that either during or prior to the time that MCF7AD was introduced into
the laboratory the line was either mixed or cross-contaminated with a faster
growing cell line. Investigation of this cell line was not pursued further.
A2780AD has been previously authenticated (McLaughlin PhD Thesis)
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MCF7AD MCF7
Figure 3. DNA fingerprinting of MCF7 and MCFAD using hinfl digest.
Genomic DNA was isolated from 107 MCF7 and MCF7AD cells. The
extracted DNA was digested to completion using the restriction endonuclease
hinfl. After electrophoresis the DNA fragments were southern blotted and probed
using the multilocus probe 33.15. The digest patterns detected differ between the
2 cell lines suggesting that the MCF7AD cell line is not derived from the
parental MCF7 line.
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3.4. Doxorubicin resistance in the chromosome 3
transferred derivative of A2780/CP70
Doxorubicin sensitivity was compared between parental A2780, A2780/Cp70, the
chromosome 3 transferred derivative A2780CP70/ch3 and the chromosome 2
transferred derivative A2780/Cp70/ch2. A2780/Cp70/ch2 was used as a control
for the chromosome transfer process. A2780/CP70 derivatives which had
undergone microcell mediated transfer of chromosome 3 and of chromosome 2
were kindly donated by M Illand (CRC Department of Medical Oncology, BOC,
Glasgow). Doxorubicin resistance was assessed by performing colony forming
assay over a range of doxorubicin concentrations. At least 15 plates of 103 cells were
exposed to doxorubicin at each dose point. Mean survival fractions were calculated for
each dose point by dividing the number of colonies formed following exposure to
doxorubicin by the numbers of colonies formed by the controls (cells which were not
exposed to doxorubicin). Doxorubicin dose/response curves are shown in figure 4,
error bars represent +/- one standard error of the mean. Mean IC50 values and
MLH1 status are shown in table 4.
Chromosome 3 transfer into A2780/CP70 resulted in restoration of doxorubicin
sensitivity to parental A2780 levels, as shown in figure 4. A2780/CP70 and
A2780/CP70ch3 are significantly more sensitive to doxorubicin than A2780/Cp70
and A2780/CP70ch2 as determined by two-tailed Students t-test (p<0.01) No
significant difference in sensitivity was observed between the values obtained for
A2780/CP70 and the chromosome 2 transferred derivative.
Doxorubicin resistance has previously been associated with alteration in DNA





Figure 4. Doxorubicin dose/response curves for A2780, A2780/CP70/chromosome 3,
A2780/CP70/chromosome 2 and paternal A2780.
Doxorubicin dose/response curves derived using clonogenic assay. At least 15 repeat
colony forming assays of 103 cells were plated out ( a total of at least 1.5 xlO4 cells) and
exposed to doxorubicin at each dose point over 3 separate experiments. Mean survival fraction
calculated by dividing mean number of surviving colonies on each plate by the mean number
of colonies formed on the no drug control plates for each dose point. Error bars represent
+/- one standard error of the mean
Introduction of chromosome 3 into A2780/CP70 restores doxorubicin sensitivity.
75
Cell line Mean IC 50
(nM)
SE mean RF MLH1 status
A2780 4 0.35 +
A2780/CP70 6.4 0.52 1.6 ~
A2780/CP70
+ chromosome 3
4.2 0.22 1.05 +
A2780/CP70
+chromosome 2
6.8 0.3 1.7 -
Table 4. Relative doxorubicin resistance of A2780/CP70, A2780/CP70/chromosome 3,
A2780/CP70/chromosome 2 and parental A2780.
IC 50 values were derived from dose response curves obtained from 3 separate experiments in which
a total of at least 15 repeat colony forming assays (1.5 x 10 4 cells) were performed at each dose point.
Chromosome 3 transfer into A2780/CP70 restores doxorubicin sensitivity.
76
chromosome 3 it could be argued that the restoration of doxorubicin sensitivity
observed is due to altered topoisomerase II activity. Topoiomerase II activity was,
therefore, compared between the cell lines. The topoisomerase II activity of crude
nuclear extract was measured using an activity assay kit obtained from TopoGen
Inc., Ohio ( described in Materials and Methods). Activity of topoisomerase II
is observed through the enzymes ability to decatenate kinetoplast DNA (kDNA)
as shown overleaf. Kinetoplast DNA is mitochondrial DNA from Crithodia
fasciculata and consists of networks of 2.5kb rings catenated together.
Topoisomerase II can monomerise these rings via its catalytic, ATP-dependent
cycle of cleavage, strand passage and religation. The amount of topoisomerase II
within a cell will therefore determine how much of the kDNA is decatanated.







Figure 5. Schematic diagram of Topoisomerase II activity Assay
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When reactions are resolved on an agarose gel, the monomeric circles of DNA
migrate much faster than catenated circles and therefore move further within the
gel. Any remaining networks of kDNA stay in the wells as they are not able to
migrate. Three situations may arise: Lane 1 indicates the result if an extract
containing high topoisomerase activity is used, almost all the kDNA will be
monomerised. Low activity is shown in lane 2 where most of the kDNA remains
catenated. An extract containing no activity would give lane 3. Activity was
expressed as the protein concentration (of nuclear extract) at which almost all
kDNA was monomerised (as in lane 1) and assessed over 3 separate
experiments. Results are summarised in table 5 and figure 6. There was no
difference in topoisomerase II activity between A2780/CP70, A2780/CP70chr2
and A2780/CP70chr3.
One must be careful not to over interpret results obtained from tumour cell lines. They
represent a monoclonal population of cells with a common genetic background. This is
not the case in a tumour, which may contain many different tumour cell clones.
Furthermore, tumours derived from different tissues will have different genetic
backgrounds and may engage different pathways leading to apoptosis following drug
exposure. In addition, the contribution of the various mechanisms of doxorubicin
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2.2 + + +
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3.9 + + +








3.75 + + +
2.5 + + +
1.25
0.7
Table 5. Comparison of topoisomerase activity between A2780, A2780/CP70,
and A2780/Cp70/ch3
Activity was expressed as the protein concentration (of nuclear extract) at which
almost all kDNA was monomerised. Summary of 3 separate experiments
+ = kDNA monomerised
- = kDNA catenated
No change in topoisomerase II activity between the A2780/CP70 derived cell lines
Catenated kDNA
Decatanated kDNA
Figure 6. Topoisomerase activity in nuclear extracts of A2780/CP70
Lanes 1 to 6 represent topoisomerase II activity at 6.6 5.2 3.9 2.6 1.3 and
0.7 ug/ul nuclear extract
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3.5. Conclusions
• The breast cell line MCF7AD was not genetically related to MCF7 and
therefore not derived from it. Evidence for loss of MMR in acquired
doxorubicin resistance rests with the solitary doxorubicin derived ovarian cell
line A2780AD.
• Chromosome 3 transfer into the ovarian cell line A2780/CP70 results in re-
expression of MLH1 and restoration of doxorubicin sensitivity. This appears
to be independent of the chromosome transfer process since the chromosome
2 transformant did not show any difference in sensitivity from A2780/CP70.
The observation that restoration of MMR activity in a MLH1 deficient cell
line restored drug sensitivity supports a direct role for MLH1 in doxorubicin
induced cell death and argues against doxorubicin resistance arising due to
increased mutation at drug resistance genes.
• Topoisomerase II activity is unaffected by chromosome 3 transfer into
A2780/CP70 and is therefore unlikely to be responsible for restoration of




RESISTANCE IN MISMATCH REPAIR DEFICIENT
STRAINS OF S. CEREVISIAE.
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4.1. Introduction
The results obtained in Chapter 3 support a direct role for loss of mismatch
repair in the development of resistance to doxorubicin. They were, however,
obtained from only one tumour cell line (A2780) and provide information on
only one component of the MMR system, MLH1. The yeast S. cerevisiae has
been extensively used as a model to investigate repair of mismatched DNA
formed during replication and recombination (Hunter and Borts, 1997; Kolodner,
1996). Using a yeast model has several advantages:
1. The complete genome sequence of S. cerevisiae has been known since April
1996 (Goffeau et al. 1996). The small size of the genome (12 Mb) and the
ease with which it can be manipulated using recombinant DNA techniques
makes it possible to generate specific deletion mutants. By disabling a single
gene the function of one and only one protein is eliminated and can be
studied (Oliver, 1998).
2. Many of the genes that are frequently altered in tumours have structural or
functional homologues in yeast. There is significant conservation of function
between yeast and human components of the DNA mismatch repair and cell
division pathways with a large body of published research. In S. cerevisiae 3
of the 6 MutS homologues (MSH2, 3 and 6) and two of the 4 MutL
homologues (PMS1 and MLH1) have been shown to play a role in MMR
(Kolodner and Marsischky, 1999; Prolla et al. 1994). This makes it a suitable
model for studying MMR.
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3. Screening drugs against yeast mutant panels is an established technique.
Quantitative comparison can be made between mutant isogenic strains of S.
cerevisiae to evaluate the effect of a given mutation on drug sensitivity
(Hartwell et al. 1997).
4. Results from colony forming assays using S. cerevisiae are available within
6 days (see Materials and Methods) making this a rapid and convenient
technique.
There are limitations to using a yeast model and the results obtained in yeast must
be interpreted with caution. Results obtained from yeast are only relevant if
analogous defects occur in human tumours. Drug sensitivities identified in yeast
may not necessarily be extrapolated to tumours. Mammalian cells may have
different damage response pathways not present in yeast (for example oncogene
mediated apoptosis) or mechanisms of resistance such as the expression levels of
p-glycoprotein (discussed in Introduction).
Isogenic haploid strains of S. cerevisiae which had disruption of specific MMR
genes were examined for sensitivity to doxorubicin. These strains were obtained
from Dr Rhona Borts, a description is provided in Materials and Methods. The
mutants were used to determine if loss of expression of the known MMR
proteins has a direct effect on sensitivity to doxorubicin. Copies of the MLH1
gene were introduced into the mlhl mutant strain resulting in re-expression of
MLH1. To determine if loss of MLH1 plays a direct role in sensitivity to
doxorubicin, drug sensitivities were compared between the scmlhl mutant and
the scmlhl mutant strain containing copies of the MLH1 gene.
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4.2. Aims of this chapter:
• To assess the effect on doxorubicin sensitivity, in a S. cerevisiae model of
disrupting the genes for MLH1, MSH2, MSH3 and MSH6.
• Using the Mlhl disrupted isogenic strain of S. cerevisiae to assess the impact
on doxorubicin sensitivity of re-introducing a wild type MLH1 gene.
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4.3. Doxorubicin resistance in mismatch repair deficient
strains of S. cerevisiae
Isogenic, haploid, strains of S. cerevisiae with disruption of the genes encoding
for the mismatch repair proteins MLH1, MSH2, MSH3 and MSH6 were exposed
to a range of doxorubicin concentrations for 24 hours. Doxorubicin dose/response
curves were derived using colony forming assay. 5 repeat assays for each strain
at each dose level were counted. The plating efficiency was calculated for each
strain by dividing the number of colonies formed by the controls (which had no
exposure to doxorubicin) by 400 (the number of cells plated out). For each
strain the mean survival fraction was determined by comparing the number of
colonies formed in replicates of doxorubicin treated cells compared to untreated
controls. Error bars represent +/- one standard error of the mean. Figure 7.
demonstrates that disruption of the mismatch repair genesMlhl, Msh2, Msh3 and
Msh6 results in increased resistance to doxorubicin. In addition results in table 6.
demonstrate a significant difference in IC50 and IC90 values between the
disrupted strains and parental S. cerevisiae (p<0.05). A two tailed Students t-test
was used to compare the IC50 and IC90 values between mutant and wild type
strains. These results are consistent with results obtained using other DNA
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Figure 7. Doxorubicin dose/response curves for wild type and MMR mutant
strains of S. cerevisiae
Doxorubicin dose response curves derived using colony forming assay.
Mean survival fraction calculated by dividing mean value of at least 5 repeat assays (a
total of at least 2000 cells)at each drug concentration point by that for no drug control.
Curves through data points represent second order linear regression.
Error bars represent +/- one standard error of the mean











Wild type 3.2 ± 0.4 70 42.5
Mlhl 9.3 ± 0.8 150 2.9 31.2 0.001
Msh2 15 ±2.9 370 4.7 43 0.05
Msh3 4.2 ±0.2 310 1.3 91 0.03
Msh6 9.6 ±0.4 420 6 80 0.001
Mlhl +
vector
6.2 ±0.6 120 1.9 36.2 0.02
Mlhl +
pMLHl
3.2 ±0.5 30 1 55.8 0.9
Table 6. Sensitivities of MMR mutant strains ofS. cerevisiae to doxorubicin.
Doxorubicin toxicity was measured by exposing exponentially growing cells in
liquid culture for 24 hours to doxorubicin, plating out 400 cells onto YPD
medium and allowing colony formation. Mean survival fraction calculated by
dividing mean value of at least 5 repeat assays at each drug concentration by
that for no drug control.
Mean IC 50 and IC 90 values (+/- 1 S.E.M.) were obtained from doxorubicin
dose/response curves derived using colony forming assays.
The resistance factor (RF) is the resistance of a given strain at IC50 relative to the
wild-type.
P, p-value for sensitivity of mutant compared to wild-type strain assessed by two
tailed Students t-test at IC50.
Mlhl, Msh2, Msh3, and Msh6 mutant strains are less sensitive to doxorubicin than wild
type.
Introduction of MLH1 to the Mlhl mutant strain restores doxorubicin sensitivity to that
of wild type.
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4.5. Doxorubicin resistance in Mlhl transfected strains of
S. cerevisiae.
Using a high copy vector, scMLHl was transfected into the Mlhl mutant strain
of S. cerevisiae (Durant et al. 1999). Sensitivity to doxorubicin was compared
between wild-type S. cerevisiae, Mlhl mutant and the Mlhl mutant strain
containing copies of the scMLHl gene (mlhl + pMLHl). Mlhl mutant containing
the vector alone was used as a control (Mlhl + vector). All transfected strains
were obtained from S. Durant, PhD student within the group.
As detailed above, doxorubicin dose/response curves were derived using colony
forming assay. 5 repeats for each strain at each dose level were counted and
mean survival fractions determined by comparing treated and no drug controls.
Figure 8 confirms that Mlhl mutant is more resistant to doxorubicin than wild-
type S. cerevisiae. More importantly it shows that transfection with Mlhl results
in restoration of doxorubicin sensitivity to wild type levels. Mean IC50 (+/- 1
S.E.M.) values are shown in Table 6. Comparison of IC50 values between Mlhl
mutant and the Mlhl + vector strain using a two tailed Students t-test shows a
significant increase in sensitivity (p<0.05) to doxorubicin. This implies that the
transfection process alone, or clonal variation, may be effecting drug sensitivity.
Transformation of the MLH1 gene into the Mlhl mutant strain resulted in
restoration of doxorubicin sensitivity to wild-type levels. Furthermore, there was a
significant difference between IC50 values obtained from Mlhl+ vector compared
to the Mlhl + pMLHl (p<0.05) suggesting that the increased sensitivity was not
entirely due to the transfection process. This study provides further confirmation
of a direct role for MLH1 in doxorubicin induced cell death.
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Figure 8. Doxorubicin dose/response curves for wild type and mlhl mutant strains of
S. cerevisiae.
Doxorubicin dose response curves derived using colony forming assay.
Mean survival fraction calculated by dividing mean value of at least 5 repeat assays (a
total of at least 2000 cells) at each drug concentration point by that for no drug control.
Curves through data points represent second order linear regression.
Error bars represent +/- one standard error of the mean.
Introduction ofMLHl increases sensitivity to doxorubicin in the mlhl mutant strain.
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4.6. Conclusions
• Genetic inactivation of the MMR genes MLH1, MSH2, MSH3 and MSH6 in
isogenic strains of S. cerevisiae leads to decreased sensitivity to doxorubicin.
These results are in keeping with results obtained using other anticancer
drugs cisplatin and carboplatin, thus supporting a role for loss of MMR
activity in drug resistance.
• Sensitivity to doxorubicin is increased in Mlhl mutant strains by the
reintroduction of the MLH1 gene providing further confirmation of a direct
role for MLH1 in doxorubicin induced cell death.
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CHAPTER 5
CHARACTERISATION OF MISMATCH REPAIR IN




The data presented in the preceding two chapters suggests that loss of MMR
results in resistance to doxorubicin. The questions remain, however, does
exposure to doxorubicin induce loss of MMR and how frequently does this
occur?
Only one cell line has been shown to have lost MMR activity and MLH1
expression as a result of serial exposure to doxorubicin (Drummond et al. 1996).
A2780AD was derived from the chemo-naive, human ovarian carcinoma cell line
A2780 by repeated exposure to doxorubicin (Rogan et al. 1984). In order to
determine the frequency of loss of MMR activity as a result of doxorubicin
exposure two new sets of doxorubicin resistant derivatives were developed. Cell
lines were derived from clonal populations of A2780 and the breast carcinoma
cell line MCF7.
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5.2. Aims of this chapter:
• To independently derive 20 doxorubicin resistant cell lines by serial exposure
of A2780 and MCF7 parental cell lines to increasing concentrations of
doxorubicin.
• To determine the frequency of loss of MMR activity in the doxorubicin
resistant cell lines.
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5.3. Development of doxorubicin resistant A2780 and
MCF7 cell lines against increasing concentrations
of doxorubicin
Two sets of doxorubicin resistant cell lines were developed by serial exposure of
A2780 and MCF7 cell lines to increasing concentrations of doxorubicin. To
reduce the influence of genetic differences between cells on the resistant
phenotype clonal populations were used. The concentration for the initial
selection was based on a surviving fraction of 30%, derived from initial
parental dose response curves. This was lOnM in both cases. Further selections
against increasing doses of doxorubicin were performed as detailed in Materials
and Methods. All drug selections were run in parallel. The derived cell lines
were maintained in doxorubicin free medium, with frozen stocks suspended in
10% DMSO.
5.4. Measurement of the level of resistance to
doxorubicin in A2780 and MCF7 derived
cell lines.
Correlation of loss of MMR activity with selection for drug resistance first
requires proof of the development of stable resistance to doxorubicin. To this
end doxorubicin sensitivity was compared between the derived cell lines A1 to
A10 and Ml to M10 and their respective parental cell lines A2780 and MCF7.
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5.4.1. Clonogenic Assay: Single dose exposure
One method of determining the level of doxorubicin resistance of the derived
A2780 and MCF7 cell lines is to assay cell survival after exposure to
doxorubicin. This assay depends on the demonstration of the reproductive
integrity of the surviving cells as evidenced by clonogenicity. Five plates of 10'
cells per cell line were exposed to a single dose of doxorubicin. The doses of
doxorubicin selected were 50nM for MCF7 derived cell lines and 15nM for A2780
derived cell lines (see Materials and Methods). Control plates of cells, which were
not exposed to doxorubicin, were set up for each cell line. This experiment was repeated
3 times resulting in a total of 1.5 x 104 cells from each cell line being exposed to
doxorubicin. In an attempt to demonstrate the stability of any doxorubicin
resistance observed, the cells were maintained in doxorubicin free medium
between each experiment, thus removing them from drug induced selection
pressure.
The cumulative data on all clonogenic survival assays is presented in figures 9,
10 and table 7. Figures 9 and 10 display in diagrammatic form the fraction of
cells surviving compared to untreated cells. Each column represents the mean of
at least 15 plates (a total of 1.5 x 104 cells) per cell line. A2780 and MCF7 show
the smallest surviving fractions (SF) indicating that they are more sensitive to
doxorubicin than their derived cell lines p < 0.001, as assessed by a two-tailed
Students t-test.
The mean surviving fractions (± 1 standard error of the mean) for each cell line
compared to their respective parental cell line are shown in Table 7 confirming
the data in figures 9 and 10. The plating efficiency was calculated by dividing the
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number of colonies formed by the controls (which had no exposure to
doxorubicin) by 1000 (the number of cells plated out). The mean plating
efficiency ranges between 25 to 75% for A2780 and 32 to 68% for MCF7
derived cell lines. This suggests that poor plating efficiency did not influence our
results in any one cell line.
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Figure 9. Clonogenic determination of doxorubicin resistance in MCF7 and
derived cell lines
For each cell line the mean survival fraction was determined by comparing the number
of colonies formed in replicates of doxorubicin treated cells (50nM over 24 hours
compared to non-treated control. A total of 1.5 x 104 cells from each cell line were treated
with doxorubicin. Error bars represent one standard error of the mean.
All derived cell lines are less sensitive to doxorubicin than parental MCF7.
Figure 10. Clonogenic determination of doxorubicin resistance in A2780 and
derived cell lines
For each cell line the mean survival fraction was determined by comparing the number
of colonies formed in replicates of doxorubicin treated cells (15nM over 24 hours)
compared to non-treated controls. A total of 1.5 x 104 cells from each cell line were treated
with doxorubicin. Error bars represent one standard error of the mean.
All derived cell lines are less sensitive to doxorubicin than parental A2780
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A2780 0.14 ±0.02 65
A1 1.02 ±0.09 25
A2 0.99 ± 0.02 46
A3 0.99 ± 0.03 64
A4 1.07 ±0.06 41
A5 1.04 ±0.09 56
A6 0.83 ± 0.03 75
A7 0.9 ±0.06 66
A8 0.98 ±0.014 58
A9 0.89 ±0.01 67
A10 0.87 ±0.02 49




MCF7 0.04 ± 0.002 61
Ml 0.8 ± 0.06 42.6
M2 0.93 ±0.16 31.6
M3 1.02 ±0.07 65.9
M4 0.61 ±0.01 33.6
M5 1.0 ±0.01 48
M6 0.92 ± 0.04 52.5
M7 1.06 ±0.09 41.3
M8 0.74 ± 0.06 45.2
M9 0.98 ±0.1 34.9
M10 0.74 ±0.09 68.1
Table 7. Relative doxorubicin resistance of derived cell lines compared to
parental cell lines.
Colony forming assays were used to determine the cell lines sensitivities to
doxorubicin. 10 cells were plated out for each assay and exposed to 50nM
doxorubicin (MCF7) and 15nM doxorubicin (A2780) for 24 hours and then
grown in doxorubicin free supplemented RPMI medium. Results displayed are
the mean of at least 15 repeat assays i.e. a total of at least 15,000 cells plated out for
each cell line and exposed to doxorubicin, over 3 separate experiments. The colonies
were counted after 10-14 days for both (no drug) control and drug exposed cells.
The mean survival fraction was calculated by dividing the mean number of colonies
formed by the drug exposed cells by the mean number of cells formed by the controls.
The plating efficiency was calculated by dividing the number of colonies formed by
the controls by the number of cells plated out.
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5.4.2. Clonogenic Assay: Dose/response curves
The results presented above indicate that the derived cell lines are more resistant
to doxorubicin than the parental cell lines. This data, however, represents only 1
dose point per cell line. To further compare differences in doxorubicin sensitivity
two of the derived cell lines from MCF7 and A2780 were chosen at random
and exposed to a wider range of doxorubicin concentrations. At least 10 plates of
103 cells were exposed to doxorubicin at each dose point. Mean survival fractions were
calculated for each dose point and the results are shown in figures 11 and 12.
A6 and A9 were significantly more resistant than A2780 (p < 0.001), thus
confirming that the derived lines had indeed acquired a resistant phenotype, see
figure 12. M3 and M6 were significantly more resistant than the parental MCF7
(p < 0.001) shown in figure 13.
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Figure 11. Doxorubicin dose/response curves for A2780 and its derived
cell lines A6 and A9.
Doxorubicin conc. (nM)
Figure 12. Doxorubicin dose/response curves for MCF7 and its derived
cell lines M3 and M6.
Doxorubicin dose response curves derived using colony forming assay. At least 10 repeat colony
forming assays ( at least 1 xlO4 cells)were plated out and exposed to doxorubicin at each dose
point. Mean survival fraction calculated by dividing mean number of surviving colonies on each
plate by the mean number of colonies formed on the no drug control plates for each dose point.
Error bars represent +/-one standard error of the mean.
The derived cell lines are less sensitive than parental A2780 and MCF7 to doxorubicin.
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5.5. Characterisation of mismatch repair protein
expression in the doxorubicin resistant derivatives
of A2780 and MCF7
5.5.1. Western Immunoblot
Initially, the doxorubicin resistant cell lines were examined for expression of the
mismatch repair proteins MLH1, PMS2 and MSH2. These were chosen as
complete loss of expression of MLH1 and PMS2 had been demonstrated in 9 out
of 10 independent cisplatin resistant derivatives of A2780 (Brown et al. 1997).
Furthermore, human colon, endometrial and ovarian cancer cell lines deficient in
MLH1 or MSH2 expression were less sensitive to cisplatin than sublines in
which the MMR deficiency was complemented by chromosome transfer (Aebi et
al. 1997; Durant et al. 1999). Western immunoblot of cell line extracts was
performed using commercially available specific monoclonal antibodies to
hMLHl, hPMS2 and hMSH2 (as detailed in Material and Methods). Protein
extract from the cell lines A2780 (positive for MLH1, PMS2 and MSH2),
A2780/CP70 (negative for MLH1 and PMS2) and LoVo colon cancer cell line
(negative for MSH2) were used as controls (Mackean et al. 1998). Equal amounts
of protein were loaded on to the gels.
The results of the hMLHl, hPMS2 and MSH2 immunoblots are shown in
figures 13 to 15.
None of the cell lines appeared to have completely lost mismatch repair protein
expression although given the quality of the western immunoblots it is impossible to say
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if there is any evidence for a difference in the level of protein expression between the
cell lines.
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Figure 13. Basal levels of MLH1 protein in A2780, MCF7 and derived cell lines
selected for resistance to doxorubicin.
Western immunoblot representing basal levels of MLH1 (Molecular Wt 80 kDa) in A2780,
MCF7 and their doxorubicin resistant derivatives.
Equal amounts of protein were analysed per cell line.
No evidence for complete loss of MLH1 expression in derived cell lines.
Figure 14. Basal levels of PMS2 protein in A2780 and derived cell lines selected
for resistance to doxorubicin.
Western immunoblot representing basal levels of PMS2 (Molecular Wt. 95 kDa) in A2780
and its doxorubicin resistant derivatives. Equal amounts of protein were analysed per cell line.
No evidence for complete loss of PMS2 expression in derived cell lines.
MCF7 data not shown (no loss of PMS 2 expression)
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Figure 15. Basal levels of HMSH2 protein in A2780, MCF7 and derived cell lines
selected for resistance to doxorubicin.
Western immunoblot representing basal levels of MSH2 (Molecular Wt. 100 kDa) in A2780.
MCF7 and their doxorubicin resistant derivatives.
Equal amounts of protein were analysed per cell line.
No evidence for complete loss of MSH2 expression in derived cell lines.
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5.5.2. Immunohistochemical detection of hMLHl protein in
doxorubicin resistant derivatives of A2780 and MCF7
Western immunoblotting can demonstrate the presence and relative quantity of
protein antigens within a cell. The sensitivity of this technique can be affected
by such variables as the method of protein extraction or by protein denaturation.
Furthermore, immunoblotting does not tell us about the subcellular location of
the protein. Immunohistochemical detection of proteins in whole cells not only
provides another method by which the presence or absence of a protein can be
identified, but also gives information as to the subcellular localisation of the
protein of interest.
4 x 104 cells from each cell line were prepared by the method detailed in
Materials and Methods. Analysis of the cells treated with hMLHl antibody was
performed using confocal microscopy. Propidium iodide was used as a
counterstain enabling identification of the nucleus within the cell. The cell lines
were examined for MLH1 expression only, as this was thought to be the most
likely MMR protein to be lost based on the experience with cisplatin derived
cell lines (Brown et al. 1997). Examples of the results are shown in figure 16.
The signal from hMLHl is localised to the nucleus and is present in all cells.
There did not appear to be any evidence of loss of hMLHl expression or of
altered subcellular location in any of the cell lines examined.
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Figure 16. Immunohistochemical detection of basal MLH1 levels in MCF7 and its doxorubicin
resistant derivative cell lines.
Confocal micrographs representing the basal expression of MLH1 protein in fixed MCF7,
M3, M5 and M6 cells. No evidence of loss of MLH1. All MLH1 localised to the nucleus.
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5.6. Characterisation of p53 expression in the doxorubicin
resistant derivatives of A2780 and MCF7
5.6.1. Introduction
Increasingly the evidence suggests that mismatch repair is necessary to engage
apoptosis in response to certain types of DNA damage. How mismatch repair is
coupled to apoptosis is not known; the theories are discussed in the Chapter 1.
At the time the data in this thesis was obtained papers linking MMR to p73
had not been published. Studies had shown that platinum resistant derivatives of
A2780 have not only lost MMR activity but had lost functional p53 and ability
to undergo p53-dependent apoptosis (Drummond et al. 1996; Anthoney et al.
1996). This suggested an association between loss of MMR and p53 function.
However, restoration of MMR activity, although it restored drug sensitivity, does
not restore p53 function (Brown et al. 1998). These data were obtained in cell-
lines treated with cisplatin; there is no published data for doxorubicin. In
addition, mutant p53 has been linked with drug resistance both in vivo and in
vitro to a range of chemotherapeutic agents including doxorubicin (Aas et al.
1996; Lowe et al. 1993; Lowe et al. 1994). Given the importance of p53 the
doxorubicin resistant derived cell lines were examined for p53 expression.
In normal, unstressed cells, p53 protein is present in extremely low levels. This
is largely due to the very short half-life (6 to 20 minutes) caused by rapid
degradation of the protein via the ubiquitin system (Levine, 1992). Mutations
affecting the p53 gene result in a stabilised protein with a much longer half life
of up to 6 hours (Bartek et al. 1990; Finlay et al. 1988). A range of antibodies
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have been raised against different epitopes of the p53 protein. These can be
used to detect the presence of the mutant protein by immunohistochemistry,
acting as a surrogate marker for the presence of mutant p53. Basal levels of wild
type p53 are usually undetectable by this method. This technique does have its
limitations and caution must be used in interpreting results. Firstly, several
studies have shown that elevated intracellular p53 can arise from an apparently
wild-type gene. This has been clearly demonstrated in the cisplatin resistant
derivative of A2780, A2780/CP70 which exhibits no mutational differences in
p53 compared to the parental line (Brown et al. 1993). Secondly,
immunohistochemical detection provides no information regarding the functional
ability of the p53 protein. Direct sequencing of p53 is more accurate but
interpretation of results are still problematic: Mutations may or may not lead to
loss of the wild type allele (Levine, 1997). P53's apoptotic activity is highly
sensitive to p53 dosage (Weinstein et al. 1997). Various mechanisms can
compromise p53 function , including extragenetic mutations in the p53 pathway
or interactions with other proteins, such as Mdm2 (Levine 1997). The
doxorubicin resistant derived cell lines were examined for p53 expression by
western immunoblot as this was the most rapid and convenient of the accepted
techniques.
5.6.2. Western Immunoblot
To determine whether there was a gross difference in the levels of p53 between
the doxorubicin resistant derived cell lines and the parental lines western
immunoblot was performed. A commercially available specific monoclonal
108
antibody to p53 DO-1 was used as detailed in Materials and Methods. Both
A2780 and MCF7 which are known to express wild-type p53, usually
undetectable by this method, were used as negative controls. A2780/CP70 was
used as a positive control. Equal volumes of protein were loaded and
immunodetection of vinculin was used to control for equivalence of total protein
on the western blot.
All of the doxorubicin resistant cell lines appear to exhibit elevated levels of
p53 protein in comparison to the parental cell lines (figure 17).
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Figure 17. Basal levels of p53 protein in A2780, MCF7 and derived cell lines
selected for resistance to doxorubicin.
Western immunoblot representing basal levels of p53 in A2780, MCF7 and their
doxorubicin resistant derivatives. Equal amounts of protein were analysed per cell line.
P53 is detectable in all the derived cell lines.
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5.7. Determination of the frequency of microsatellite
instability (MSI) in doxorubicin resistant derivatives of
A2780 and MCF7
5.7.1. Introduction
Loss of functional DNA mismatch repair results in destabilization of the genome.
This leads to high mutation rates particularly in microsatellite sequences in both
non-coding and coding portions of the genome, so-called microsatellite instability
(MSI). To date the detection of MSI has been used as the hallmark for loss of
MMR activity. Studies have demonstrated MSI both in inherited and sporadic
tumours (Aaltonen et al. 1993; Wooster et al. 1994) and in cell lines as a result of
drug exposure (Anthoney et al. 1996). Having failed to demonstrate loss of MMR
protein expression, the doxorubicin resistant cell lines were examined for MSI in
order to determine if they had lost functional MMR activity.
MSI is defined as a change of any length due to either insertion or deletion of
repeating units in a microsatellite within a tumour when compared to normal
tissue (Boland et al. 1998). In this case comparison was made between the
doxorubicin resistant derivatives and the parental cell lines. The analysis of
microsatellite repeats was performed using the polymerase chain reaction (PCR).
Certain parameters influence the success and accuracy of amplification of
microsatellite DNA and are discussed below. In each cycle of amplification the
DNA template and primer sequences go through steps of denaturation, annealing
and elongation. The temperature at which the primers anneal to the template
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strand is critical and is a function of the length and sequence context of the
primers themselves. If the temperature of the annealing step is above the optimal
annealing temperature for the specific primers then there will be a much reduced
efficiency of amplification. If it is below optimal then the primers become more
likely to anneal not only to the specific template sequences but also to non¬
specific sequences leading to an increase in non-specific amplified products. In
the analysis of microsatellite repeat sequences reported here a technique of
Touchdown PCR was used to improve the efficiency of DNA amplification (Don
et al. 1991) This technique is further discussed in Materials and Methods.
Investigating MSI is problematic:
• How many loci should be studied? And how many of these need to show
MSI before a tumour can be defined as having a particular phenotype? MSI
was initially described in inherited colonic carcinomas (HNPCC) in 1993
(Thibodeau et al. 1993; Peltomaki et al. 1993; and Aaltonen et al. 1993).
International criteria for the investigation of MSI were not established until
November 1998 (Boland et al. 1998) after the cell lines described in this
thesis had been investigated. Prior to 1998 different approaches and criteria
were used depending on which group had published the paper. Some
considered 1 locus in 12 to be sufficient (Toyama et al. 1996), whilst others
considered over 30% of loci examined to be appropriate (Thibodeau et al.
1996). This lead to the situation whereby the mutation rate in normal tissues
such as peripheral T-lymphocytes, which may be as high as 3 x 10 3 per
allele, was similar to that observed in some sporadic tumours labelled as
displaying MSI (Hackman et al. 1995; Hearne et al. 1992).
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• High or low frequency MSI ? In colonic tumours there appears to be two
levels of MSI depending on the number of markers displaying MSI and on
the degree of increase or decrease in the fragment size. High frequency MSI
(MSI-H) is characterised by widespread instability with a majority of markers
exhibiting instability. Low frequency MSI (MSI-L) is characterised by a
minority of markers exhibiting MSI (Lothe et al. 1993; Dietmaier et al. 1997;
Thibodeau et al. 1998). MSI-H has been shown to be associated with
mutations in MSH2, MLH1 and PMS2 (Borrensen et al. 1995; Liu et al.
1995,1996; Wu et al. 1997). Less clear are the mechanisms underlying MSI-L.
Based on observations in yeast MSH3 and MSH6 have been implicated in
the phenomenon (Marsischky et al. 1996). MSH6 mutant human tumours and
cell lines show MSI at lower levels than tumour cells with mutation in
MSH2 and MLH1 (Papadopoulous et al. 1995; Percesepe et al. 1998). The
presence of and molecular basis for a non-colonic MSI-L and MSI-H group
of tumours remains to be established. Given that the cohort of human genes
responsible for MSI is not fully known and that the doxorubicin derived cell
lines do not appear to have lost expression of MLH1, MSH2 and PMS2 it is
important to identify cell lines displaying MSI-L in order to investigate the
underlying MMR pathway. Several issues, however, are not clear:
• Are the results obtained from colonic and other tumours applicable to the
development of drug resistance in cell lines? Only one paper has been
published examining MSI in the context of drug resistance (Anthoney et al.
1996).
• Which loci? The chances of discovering MSI are highly dependent on which
loci are studied (Boland et al. 1998).
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5.7.2 Results
On the basis of the available literature, 5 loci were examined in the doxorubicin
resistant cell lines and compared to their respective parental cell line. If MSI
was found at 2 or more loci the cell line was judged to exhibit a MIN+
phenotype (Sometimes referred to as a replication error, RER+, phenotype). If MSI
was observed at less than 2 loci the number of loci examined would be
expanded to 10. Each cell line was examined for alterations in the length of CA
microsatellite repeats on chromosomes 2, 3 and 17. The choice of PCR primers
was made on the basis of work carried out by G Hirst (personal communication)
and A Anthoney (Anthoney et al. 1996) on doxorubicin and cisplatin resistant cell
lines. Primers were chosen which were reliable and had demonstrated MSI in
A2780AD, A2780CP70 or platinum resistant derivatives of A2780 as summarised
in Table 8.
When analysis of microsatellite repeats at 10 loci was performed only one cell
line MCF7/M6, at one locus D2S391 displayed MSI, figure 18. All the other cell
lines did not exhibit any evidence of microsatellite mutation at the loci studied.
Examples of the resulting autographs can be seen figures 18 and 19. The presence
of fainter, so-called stutter, bands represent artefacts that arise during PCR by
several different mechanisms (Tautz, 1990). The results are summarised in table 9.
These results indicate that the observed doxorubicin resistance in these 20 cell
lines is unlikely to be associated with the loss of DNA mismatch repair activity.
Loss of MMR following doxorubicin exposure must occur at a very low
frequency given that A2780AD remains the only cell line which has lost MLH1
expression.
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LOCUS A2780 A2780AD A2780/CP70
D2S119 ■ ■ ■
D2S121 ■ NA ■
D2S136 ■ ■ ■
D2S391 ■ ■ ■
D3S1582 ■ ■ ■
D3S1606 ■ ■ ■
D3S1612 ■ ■ ■
D3S1619 ■ ■ ■
D17S796 ■ ■ ■
D17S801 ■ ■ ■
■ No MI or LOH
■ MI no LOH
■ LOH
Table 8. Incidence of microsatellite mutation using primers located on
chromosome 2, 3 and 17 in doxorubicin and platinum resistant derivatives of











































Table 9. Incidence of microsatellite mutations in multiple step selected doxorubicin
resistant MCF7 and A2780 cell lines.
DNA from doxorubicin resistant A2780 and MCF7 cell lines, derived by selection with
increasing concentrations of doxorubicin, was amplified by PCR using microsatellite
specific primers. Mutation was characterised by a shift in the size of microsatellite DNA
compared to that from parental MCF7 and A2780.
Only 1 cell line demonstrates MSI at 1 locus. None of the doxorubicin selected cell lines
displays evidence of loss of functional mismatch repair.
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Figure 18. FCR amplification of microsatellite loci in A2780, MCF7 and their derived
cell lines selected for resistance to increasing concentrations of doxorubicin.
PCR amplification of microsatellite loci D2S391 and D3S1612 in A2780, MCF7 and
derived cell lines. The microsatellite alleles are indicated by arrows. The presence of
fainter, so-called stutter, bands occurs as a result of artefacts which arise during PCR.
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Figure 19. FCR amplification of microsatellite loci in A2780, MCF7 and their derived
cell lines selected for resistance to increasing concentrations of doxorubicin.
PCR amplification of microsatellite loci D3S1582 and D17S796 in A2780, MCF7 and
derived cell lines. The microsatellite alleles are indicated by arrows. The presence of
fainter, so-called stutter, bands occurs as a result of artefacts which arise during PCR.
No microsatellite instability is observed.
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Following publication in November 1998 (Boland et al. 1998) of criteria for
determining MSI in colorectal carcinoma it was reassuring to note that we had
inadvertently followed the main guidelines, summarised below:
1. Five microsatellites should be examined, MSI-H is characterised by finding
microsatellite instability at 2 out of the 5 loci. If MSI is observed at 1 locus
the number of markers should be expanded to distinguish MSI-L from
microsatellite stable tumours.
2. A panel of markers was identified which should be used in identifying MSI
in colonic tumours.
3. Panels of markers for other tumour types were not established due to limited
experimental information. The recommendations, however, for the examination
of breast and ovarian tumours were to, initially, consider 5 loci and that
these should consist of dinucleotide repeat sequences of DNA (breast
tumours).




Twenty doxorubicin resistant cell lines were derived independently from
clonal populations of the ovarian and breast carcinoma cell lines A2780 and
MCF7 following serial exposure to doxorubicin.
None of the doxorubicin resistant cell lines had completely lost expression of
the mismatch repair proteins MLH1, PMS2 and MSH2. A reduction in the
level of expressed proteins, however, cannot be excluded on the basis of the data
presented here.
No evidence of loss of mismatch repair activity, as detected by the presence
of microsatellite instability, could be found in these cell lines.
Loss of MMR following doxorubicin exposure must occur at a very low
frequency given that A2780AD remains the only independently derived
doxorubicin resistant cell line which has lost MLH1 expression.
Loss of MMR does not appear to be a factor in the development of resistance
to doxorubicin in these cell lines. Although a reduction in MMR protein
expression which does not result in MSI has not been excluded.
All of the resistant cell lines appeared to have elevated levels of p53 protein
in comparison to parental A2780 or MCF7 which may be implicated in the
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development of resistance. The focus of this thesis is on mismatch repair.
There is an extensive literature characterising mutant p53 in doxorubicin
resistant cell lines. Given this, further investigation at a molecular or
functional level of p53 or of other mechanisms of resistance was felt to be
outside the scope of this thesis.
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CHAPTER 6
MLH1 AND P53 EXPRESSION IN BREAST TUMOURS
PRIOR TO AND FOLLOWING CHEMOTHERAPY
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6.1. Introduction
The data presented so far suggests that the loss of expression of mismatch repair
proteins results in resistance to doxorubicin. Furthermore, re-expression of MLH1
in A2780/CP70, together with other re-expression studies, leads to sensitisation to
doxorubicin (and a variety of other drugs) supporting a direct role for MMR in
engaging in cell death ( de Alas et al. 1997; Durant et al. 1999) . It would
appear, in vitro, that loss of MMR and in particular MLH1 represents a
mechanism by which cells can acquire resistance to a variety of DNA damaging
agents. Unlike cisplatin, however, acquisition of doxorubicin resistance as a result
of exposure to the drug does not seem to result in loss of MMR (Anthoney et
al. 1996; Drummond et al. 1996). The most important question remains, is loss
of MMR a clinically relevant mechanism of drug resistance?
6.1.1. MMR protein expression and drug resistance in vivo
An increase has been reported in the proportion of ovarian tumours negative for
MLH1 observed in samples taken at second look laparotomy after cisplatin
chemotherapy (4/11) compared to untreated tumours (4/39) (Brown et al. 1997). In
addition, a 66% reduction in MLH1 expression following chemotherapy has been
reported following carboplatin or cisplatin in a study of 38 ovarian cancer
patients (Fink et al. 1998b). A recent study has shown that reduced expression of
MLH1 prior to platinum based chemotherapy predicts for poor overall survival
(Mackean et al, 1999). What are the implications in other tumour types?
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6.1.2. Breast cancer
Why study MMR in breast cancer?
• Breast cancer accounts for 1 in 5 of all deaths in women aged between 35
and 54. Despite radical surgery, more than 50% of surgically treated patients
eventually relapse. Metastatic disease remains incurable with patients
becoming progressively less sensitive to systemic therapy.
• Anthracyclines and cisplatin are agents which are commonly used in the
treatment of breast cancer. Resistance to these drugs is a considerable
clinical problem.
• Chemotherapy before surgery (so-called primary or neoadjuvant chemotherapy)
is increasingly being used in the treatment of primary breast cancer. Its
effectiveness in inducing tumour regression and thus allowing more
conservative surgery (particularly avoidance of mastectomy) is well
established (Smith and A1 Moundhri,1998; Bonadonna et al. 1998; Smith et al.
1995). During therapy the tumour response can be directly measured and
thus can be used as a surrogate marker of drug sensitivity. Furthermore,
treatment occurs between initial biopsy and definitive surgery allowing a
system to study, in vivo, the effect of chemotherapy on tumour biology
(Daidone et al. 1995; Linn et al. 1997; Frassoldati et al. 1997). This is a similar
approach to that used to investigate MMR protein expression in ovarian
cancer.
In order to study mismatch repair in breast cancer should we be using MSI analysis or
detection of MMR protein expression by immunohistochemistry?
MSI analysis in tumours is dependent on a number of factors:
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1. The availability of suitable biopsy material. That is, tissue from which DNA
can be extracted with low amounts of contamination from normal cells.
2. The availability of a normal control. In order to determine if MSI is present
DNA from normal tissue is required to compare with the tumour DNA.
3. The assumption that drug resistance correlates with MSI. The pathways from
MMR to apoptosis remain unknown. It is possible that changes in MMR
protein expression could influence apoptosis without leading to MSI.
4. Which loci? As discussed in the preceding chapter there are inherent
problems in examining for MSI.
Detection of MMR protein expression by immunohistochemistry allows archival
paraffin embedded tissue to be studied. Furthermore, tumour cells within the
sample can be directly identified using light microscopy. This technique was first
used by Wilson in 1995 (Wilson et al. 1995). In 1996 Thibodeau et al showed
that, in paraffin embedded colorectal tumour samples, immunohistochemical
staining for MLH1 and MSH2 corresponded very closely with loss of function
of these genes as detected by MSI. All 14 tumours which had lost
immunohistochemical staining were found to exhibit MSI, giving a low false
positive rate and 100% specificity. 5 out of the 14 tumours with normal
histochemistry had MSI, giving a sensitivity of 64% (Thibodeau et al. 1996). As
discussed earlier loss of MLH1 and MSH2 are not the only causes of MSI.
Subsequent studies have confirmed the validity of this technique in other tumour
types (Mackean et al. 1999; Pare, 1999; Hartman et al. 1999, Friedrich et al, 1999).
It is not known what level of expression of MMR proteins is required to affect
immunostaining or to produce MSI.
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6.1.3. P53
Mutation of the tumour suppressor gene p53 is a frequent genetic change in
breast cancer (Elledge and Allred, 1994). Although the results of studies vary,
mutant p53 is generally viewed as an indicator of poor prognosis in breast
cancer (Isola et al. 1992; Thor et al. 1992). As discussed in the preceding
chapters it has been postulated that mutation of p53 may play a role in the
development of resistance to chemotherapy. An in vitro study examining
chemosensitivity in human breast cancer specimens reported a correlation
between mutant p53 protein expression and enhanced chemoresistance (Koechli et
al. 1994). These findings have not been supported in clinical studies, with mutant
p53 failing to act as an indicator of response to chemotherapy (Makris et al. 1997;
Rozan et al. 1998; Makris et al. 1995). Loss of functional p53 has been observed
in association with loss of the MMR protein MLH1 in experimental models
(Drummond et al. 1996; Anthoney et al. 1996).
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6.2. Aims of Chapter:
• To investigate, using immunohistochemistry, MLH1 and p53 expression in
sporadic breast cancer.
• Using paired samples obtained prior to and following neoadjuvant
chemotherapy examine the effect of chemotherapy on MLH1 and p53
expression.




Archival paraffin embedded material was obtained from 36 patients treated with
neoadjuvant chemotherapy for primary breast cancer between 1993 and 1997.
Samples were obtained from either the Beatson Oncology Centre, Glasgow or
the Western General Hospital Edinburgh. Samples consisted of a tru-cut biopsy
taken at the time of diagnosis and tumour taken at mastectomy following
chemotherapy. Of the 36 patients paired samples were available for 29; for
seven patients, paired biological determinants were not available because of the
few or no tumour cells present in their samples. Median age of the patients was
47 years (range, 26 to 66 years) The median maximum tumour diameter at
diagnosis was 6cm (range 2.9-15cm). Other patient characteristics are as listed in
table 10.
Eleven patients received continuous-infusion 5-fluorouracil 200mg/m2 /day,
doxorubicin 50mg/m2, and cyclophosphamide 600 mg/m2 every 3 weeks (FAC);
16 patients received doxorubicin 20-30 mg/m2 / week and continuous-infusion 5-
fluorouracil 200mg/m2/day (AcF); and nine patients received epirubicin 50 mg/m2
and cisplatin 60 mg/m2 three times weekly and continuous-infusion 5-fluorouracil
200mg/m2 /day (ECF). All patients completed at least 9 weeks of treatment before
the repeat biopsy at surgery. Radiotherapy was administered according to local
practice after both chemotherapy and definitive surgery. Those who were
oestrogen receptor-positive were placed on tamoxifen. Response was assessed by
bidimensional tumour measurement obtained retrospectively from patients case
records, according to International Union Against Cancer Criteria (UICC), and
maintained over at least 4 weeks (Hayward et al, 1977) UICC. Oestrogen receptor
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b. ER, Oestrogen Receptor
c. Response: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
Table 10 Patient characteristics.
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(ER) status was obtained from patients pathology records. Median follow-up
was 41 months (range 30 to 66 months).
6.4. Immunohistochemistry
Immunohistochemistry was performed on histology sections taken from tru-cut
biopsy and mastectomy specimens as detailed in Materials and Methods.
Samples were examined, where ever possible for MLH1 and p53 expression.
6.4.1 Storage of samples.
Several studies have demonstrated that loss of antigenicity occurs following
prolonged storage of paraffin-embedded sections on glass slides (Prioleau and
Schnitt, 1995; Jacobs et al. 1996). This has been demonstrated in a variety of
different tissue types (including breast) and for a variety of different antigens
(including p53) (Bertheau, 1998). Antigen loss has been shown to be
significantly greater over time when slides are stored at room temperature as
compared to 4°C (Jacobs et al. 1996). Slides in this study were therefore stored
at 4°C and used within a short period of time after being cut.
6.4.2. Scoring of slides
Slides were scored for intensity and percentage cells staining as detailed in
Materials and Methods by Dr M. Rawhilly (Consultant Pathologist). The
reporting of immunohistochemistry has been a subject of heated debate for many
years. Most of the studies focus on Oestrogen receptor (ER) analysis in breast
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cancer. The most commonly reported combined intensity and percentage score is
the H-score (McLelland, 1990) calculated by:
H-score = (% of cells stained at intensity category lx 1) + (% of cells stained at
intensity category 2x2) + (% of cells stained at intensity category 3x3)
This has been shown to give a closer correlation with the gold standard,
biochemical, assay for detecting ER status than either intensity or percentage
staining as assessed by immunohistochemistry (Remmle, 1986). In another study,
Detre et al. (Detre et al. 1995) compared 3 methods of scoring immunostaining
for ER. They showed that there was no advantage to the H-score when
compared with 2 quickscores, one additive (I + %) and the second multiplicative
(I x %). Both quickscores gave as good a correlation as the, more complicated,
H-score when assessed against the gold standard enzyme immunoassay.
Furthermore, they were less time consuming. No advantage was found between
either method of assessing the quickscore. The additive method was chosen for
this thesis i.e.
I + % = IHC score.
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6.5. Changes in MLH1 and p53 expression in response to
chemotherapy
Paired breast tumour samples from the same patient before and after neoadjuvant
chemotherapy were evaluated for MLH1 immunohistochemical staining. An
example of MLH1 immunohistochemical analysis of paired samples before and
after chemotherapy is shown figure 20.
There was a significant reduction in MLH1 expression as assessed by the
percentage staining (p=0.01, n =28) and combined IHC score (p=0.01, n= 28)
following chemotherapy, shown in Table 11. Furthermore, there was a reduction in
the intensity of staining within cells seen after chemotherapy. Sixty-one percent
of patients had immunostain intensity scores of 2 or greater before treatment
compared with 36% after chemotherapy. This reduction held true for subgroup
analysis by chemotherapy regimen although it did not reach significance shown in
Table 12. Matched patient IHC, percentage and intensity staining scores prior to
and following chemotherapy are shown in figure 21.
There was no significant reduction in p53 expression following chemotherapy
shown in Table 11. Subgroup analysis of p53 IHC scores by chemotherapy
regimen also failed to show any difference pre and post chemotherapy shown in
figure 22.
There was no statistically significant correlation of percent, intensity or IHC
MLH1 and p53 scores before or after chemotherapy shown in Table 13.
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Samples taken prior to and following FAC
chemotherapy (DFS=5months).
A Pre chemo biopsy immunostained for MLH1
(brown). Counterstain haemotoxylin. IHC=5
B Post chemo sample stained for MLH1.
Counterstain haemotoxylin. IHC=0
Magnification x2()0
Figure 2(1. MLHl immunohistochemistry (A) Tru-cut biopsy before chemotherapy;
positive for MLHl staining (brown). (B) Mastectomy specimen with low MLHl
staining (blue).
Pre-chemo Post-chemo Pre vs post
(mean) (mean) p-value
MLH1 staining:
Intensity 1.7 1.3 0.06
Percentage 78 58 0.01
Intensity + Percentage 4 3 0.0099
n=28
P53 staining:
Intensity 1.1 1.0 0.16
Percentage 36.7 30.4 0.35
Intensity + Percentage 1.6 1.4 0.36
n=29
Table 11. Comparison of MLH1 and P53 immunostaining prior to and
following chemotherapy.
The within-patient comparison of MLH1 and p53 scores before and after
chemotherapy was assessed using the Wilcoxon signed rank sum test.
MLH1 expression is reduced as a result of chemotherapy.
Chemotherapy Pre-chemo Post-chemo N P
Regimen (mean) (mean)
FAC 4 2.5 11 0.07
AcF 3.8 3.2 12 0.07
ECF 4.3 3.2 6 0.06
Table 12 Comparison of MLH1 combined IHC scores prior to and following
FAC, AcF and ECF chemotherapy regimens
The within-patient comparison of MLH1 IHC scores before and after FAC, AcF,







Figure 21. Paired MLH1 scores and percentage cells staining in breast cancer samples
before and after chemotherapy
Percent and IHC (% staining + intensity) score are shown for each biopsy. Scores joined by a
line are from the same patient before and after chemotherapy
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Chemotherapy
Figure 22. Paired p53 IHC scores in breast cancer samples before and after
chemotherapy
IHC (% staining + intensity) score is shown for each biopsy. Scores joined by a line are
from the same patient before and after chemotherapy.
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6.6. Univariate and multivariate analysis
There was a highly significant correlation between poor disease free survival and
a low level of MLH1 expression as expressed by percentage staining (p= 0.0031,
n=28), intensity of staining within cells (p=0.016, n=28) and the overall IHC
score (p=0.0005, n=28) obtained in the post-chemotherapy samples using Cox
regression analysis. In addition, the difference between the pre and post-
chemotherapy scores was found to correlate with a poor disease free survival
(p=0.0007, n=27). Shown in Table 15, figures 23 and 24.
Pre-chemotherapy MLH1 expression did not predict for response to primary
chemotherapy shown in Table 14. Furthermore, neither pre-chemotherapy intensity,
percentage staining or IHC score for MLH1 predicted for disease-free survival.
Shown in Table 15.
Figures 23 and 24 shows Kaplan Meir survival curves for MLH1 expression prior
to and following chemotherapy.
Pre-chemotherapy p53 expression failed to predict tumour response to
chemotherapy (Table 14) and disease free survival (Table 15). Figure 25 shows
Kaplan-Meier survival curves for p53 IHC scores before and after chemotherapy.
The post-chemotherapy p53 score did not predict DFS (p=0.12, n=29) shown in
Table 15 and figure 25.
Analysis of individual patients with very low MLH1 expression (pre or post
chemotherapy) has shown they have a very short disease free survival. Three patients
had completely lost expression of hMLHl following chemotherapy and they relapsed at
4, 8 and 15 months respectively. Two patients had very low expression of hMLHl prior
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to chemotherapy (0 and 10% of cells positive for immunostaining) these patients
progressed at 12 months and 6 weeks respectively. Of the 7 patients for whom paired
samples were unavailable, one had achieved a complete response (pre-chemotherapy
sample 80% MLH1 positive) and remains in remission at 49 months. Of the remaining
six patients, no clear pattern emerged and the distribution of pre-chemotherapy MLH1
scores was indistinguishable from the others. The failure to produce a post-
chemotherapy hMLHl score was because of poor sample quality.
A univariate analysis of clinical characteristics is shown in tablel6. There was
an association between young age, pre-menopausal status and poor response to
chemotherapy and poor disease free survival. A forward stepwise multivariate
analysis was conducted using the statistically significant clinical features along
with MLH1 intensity, percentage staining, combined IHC score after
chemotherapy and change in IHC score (before and after). This identified
percentage staining (P = 0.019), age (P < 0.001), response to chemotherapy (P =
0.001), and menopausal status (P= 0.041) as independent prognostic factors (n =
27).
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Intensity + Percentage 0.41
Table 13 Correlation of MLH1 and P53 immunostaining.
There is no association between MLH1 and p53 expression as assessed by
Spearman's rank correlation coefficient
N Tumour Response
p-value
Pre-chemo MLH1 staining: 35
Intensity 0.14
Percentage 0.9
Intensity + Percentage 0.39
Pre-chemo P53 staining: 32
Intensity 0.4
Percentage 0.15
Intensity + Percentage 0.95
Age 36 0.57
Histological grade 30 0.31
Oestrogen receptor status 30 0.79
Menopausal status 36 0.39
Lymph node status 35 0.39
Table 14. Tumour response to chemotherapy and prognostic factors
The univariate examination of the association between tumour response and p53,
MLH1 and clinical factors was made using the Cox Regression Analysis.
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Prognostic Factor N DFS
p-value
Pre-chemo MLH1 staining: 35
Intensity 0.31
Percentage 0.33
Intensity + Percentage 0.39
Post-chemo MLH1 staining: 29
Intensity 0.016
Percentage 0.0026
Intensity + Percentage 0.0005
Pre-Post MLH1 score 29 0.0007
Pre-chemo P53 staining: 32
Intensity 0.24
Percentage 0.34
Intensity + Percentage 0.31
Post-chemo P53 staining: 29
Intensity 0.11
Percentage 0.26
Intensity + Percentage 0.12
Table 15. Disease free survival, p53 and MLH1 expression
The univariate examination of the association between disease free survival and
p53 and MLH1 expression was made using the Cox Regression Analysis.
Prognostic factor N DFS
p-value
Age 36 0.001
Menopausal status 36 0.03







Histological grade 30 0.28
Oestrogen receptor status 30 0.47
Table 16. Disease free survival and clinico-pathological factors
The univariate examination of the association between disease free survival and
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Figure 23. Kaplan Meier survival curves for MLH1 IHC scores and percentage cells staining
prior to and following chemotherapy.
Kaplan Meier survival curves for MLH1 IHC scores pre-chemotherapy (A) and post-chemotherapy (B).
The proportion of patients disease free is shown against time (months). MLH1 scores of 3 and less are
shown with a dashed line and scores greater than 3 with a solid line.
















































Figure 24. Kaplan Meier survival curves for MLH1 intensity prior to and following
chemotherapy.
Kaplan Meier survival curves for MLH1 intensity pre-chemotherapy (A) and post-chemotherapy
(B). The proportion of patients disease free is shown against time (months). MLH1 intensity of 1















































Figure 25. Kaplan Meier survival curves for p53 IHC scores prior to and following
chemotherapy.
Kaplan Meier survival curves for p53 IHC scores pre-chemotherapy (A) and post-chemotherapy
(B). The proportion of patients disease free is shown against time (months). p53 scores of 3 and
less are shown with a dashed line and scores greater than 3 with a solid line.
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6.9. Conclusion
Loss of MLH1 expression occurs as a result of chemotherapy in vivo.
Low levels of MLH1 in breast tumours following chemotherapy independently
predicts poor disease free survival.
There is no association between p53 and MLH1 expression in vivo.
Loss of p53 expression does not occur as a result of chemotherapy.
Pre-chemotherapy MLH1 and p53 levels do not predict tumour response to
chemotherapy or disease free survival.
Post-chemotherapy p53 expression does not predict disease free survival.
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7. Summary
• For the first time, combined chemotherapy has been shown to result in loss
of expression of the MMR protein hMLHl in human breast cancer.
• Loss of expression of hMLHl following chemotherapy is a poor prognostic
indicator in patients receiving neoadjuvant chemotherapy in locally advanced
breast cancer. It acts independently of other known prognostic factors and is
a good predictor of poor disease-free survival.
• Genetic inactivation of MLH1, MSH2, MSH3, and MSH6 leads to decreased
sensitivity to doxorubicin in S cerevisiae. Furthermore, re-expression of
MLH1, as a result of gene transfer, results in increased sensitivity. This
supports a direct role for loss of MMR in resistance to doxorubicin.
• Re-expression of hMLHl as a result of chromosome transfer into the
cisplatin resistant ovarian tumour cell line A2780/CP70 increases sensitivity to
doxorubicin. This supports a direct role for loss of MLH1 in resistance to
doxorubicin in a cell line derived by exposure to another chemotherapeutic
agent.
• Complete loss of MMR does not occur as a result of exposure to doxorubicin
in the human breast and ovarian carcinoma cell lines examined, although a






8.1 Mismatch repair and drug resistance.
Increasingly the data suggests a direct role for MMR in the development of
resistance to a range of DNA damaging agents. Inactivation of the MMR genes
in yeast not only decreases sensitivity to doxorubicin but to cisplatin and
carboplatin as well. Furthermore, transformation of the yeast MLH1 gene back
into mlhl mutant strain increases sensitivity to cisplatin in addition to
doxorubicin (Durant et al. 1999). Restoration of MMR activity by chromosome
transfer into MMR-defective human colorectal (MLH1) and endometrial (MSH2)
tumour cell lines results in increased sensitivity to a number of drugs (Aebi et al.
1997; Umar et al. 1997). Here, more importantly with regard to drug resistance,
sensitivity has been examined in a cell line (A2780/CP70) which has lost MLH1
expression as a result of exposure to cisplatin. Re-expression of MLH1 in this
cell line increases sensitivity to both doxorubicin and cisplatin (Durant et al. 1999).
Furthermore, introduction of MLH1 into A2780/CP70 sensitises cells to cisplatin,
temozolomide and epirubicin when grown as a xenograft (Plumb et al. 2000). This
data suggests, accepting the limitations of yeast and cell line studies, that MMR is
directly involved in drug sensitivity, rather than the alternative hypothesis that loss of
MMR leads to higher mutation rates at drug resistance genes. Furthermore, it
implicates loss of MLH1 as a mechanism by which resistance to multiple drugs
can occur. The chromosome transfer studies emphasise the potential for drug
sensitisation by re-expression of MLH1 in drug resistant cells. How loss of
MMR leads to drug resistance is not understood and potential models were
discussed in Chapter 1.
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Why is MLH1 lost as a result of cisplatin exposure? The promoter of hMLHl
has been shown to undergo hypermethylation in tumours and cisplatin-resistant
ovarian cancer cell lines, which correlates with loss of MLH1 expression
(Strathdee et al. 1999; Herman et al. 1998; Leung et al. 1999). This may be the
basis for the high frequency of MLH1 loss, rather than other MMR proteins
observed in tumours and drug resistant models. Furthermore, hypermethylation of
the hMLHl promoter and the resultant loss of protein expression was seen at
higher frequencies in tumours that had been exposed to chemotherapy (50%
samples) than untreated samples (9%). In sporadic colon (Herman et al. 1998),
gastric (Leung et al. 1999) and endometrial (Gurin et al. 1999) cancer in which the
overwhelming majority of sporadic tumours with loss of MMR are MLH1
deficient similar results are seen, with the hMLHl promoter exhibiting
hypermethylation.
Why was loss of MLH1 observed in the doxorubicin resistant derivative of
A2780, A2780AD (Drummond et al. 1996) when the cell lines derived in this
thesis had no disruption of MMR activity? Doxorubicin and cisplatin both
produce DNA hypermethylation in vitro. Cisplatin, however, induces
hypermethylation at doses which are 100 fold lower than those required by
doxorubicin (Nyce, 1989). Hence, it may simply reflect a dose effect; if the cell lines
discussed here had been exposed to higher doxorubicin concentrations loss of MLH1
may have been induced. Alternatively, loss of MLH1 in response to doxorubicin
exposure may be a low frequency event. The most likely explanation, however,
is that loss of MLH1 expression was induced by exposure to another agent.
A2780AD was originally isolated after treatment of the A2780 cell population
with the alkylating agent EMS to induce drug resistant mutations.
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8.2. Mismatch repair and breast cancer.
Is loss of MMR a clinically relevant mechanism of drug resistance? Three
clinical studies have reported an increase in the proportion of ovarian tumours
with low expression of MLH1 as determined immunologically in samples taken
at "second look" laporotomy after cisplatin chemotherapy compared to untreated
tumours (Mackean et al. 1999, Brown et al. 1997, Samimi et al, 2000). These support
the data presented in this thesis showing loss of expression of MLH1 following
neoadjuvant chemotherapy in locally advanced breast cancer. The results
presented here are open to criticism as the patients had received 3 different
chemotherapy regimens. They did, however, all receive an anthracycline and in
some cases cisplatin containing chemotherapy. Together with the ovarian studies
this suggests that loss of MLH1 could be an important factor contributing to the
frequent development of clinical resistance in these tumour types. Why is the level
of MLH1 expression reduced following chemotherapy? There is evidence in ovarian
cancer that cisplatin induces loss of expression of MLH1 as a result of
hypermethylation of the MLH1 promoter (Strathdee et al. 1999). There is no evidence,
however, that this is the case with the anthracyclines or in breast cancer. Furthermore,
the data presented in this thesis would suggest that doxorubicin is not inducing loss of
MLH1 expression, although this clearly requires further investigation. The alternate
hypothesis is that the chemotherapy administered to these patients selects out a pre¬
existing sub-population of breast cancer cells which have low levels of MLH1
expression. Further research is ongoing to identify how MLH1 expression is reduced
following chemotherapy in breast cancer patients.
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Loss of MLH1 expression in breast cancer following chemotherapy is a
predictor of poor disease free survival and may, therefore, define a subgroup of
patients with drug-resistant breast cancer. Why does MLH1 expression prior to
chemotherapy fail to act as a prognostic indicator or to predict for tumour
response to chemotherapy? It is possible that expression analysis prior to
chemotherapy may fail due to an inability to identify resistant sub-populations
that are more readily identifiable after chemotherapy. However, notably, the two
patients who had less than 10% of tumour cells expressing MLH1 prior to
chemotherapy had rapidly progressive disease. It could be that loss of MLH1 is
a marker for other changes which result in a more aggressive phenotype or that
it represents tumour progression.
Tumours treated with neoadjuvant chemotherapy are unusual in that tissue
samples are taken prior to and following chemotherapy. For most patients only
pre-chemotherapy samples will be available and, in the case of recurrent disease,
this may have been taken several years (and chemotherapy regimens) earlier. How
useful, therefore, is a prognostic marker assessable only on post-chemotherapy
samples? It has long been known that tumour cells release DNA into the
circulation which may then be recovered from serum. Serum DNA measurements
are elevated in approximately 50% of cancer patients (Leon et al. 1977). Studies in
lung and head and neck cancer patients have demonstrated the feasibility of
collecting serum DNA and testing this for microsatellite instability using PCR
(Chen et al. 1996; Nawroz et al. 1996). MSI is a marker for MMR function (with
the caveat discussed below). Potentially, MSI analysis of serum DNA could
represent a novel way of assessing MMR function without the need for tumour
biopsy. Alternatively, in ovarian tumours treated with cisplatin, loss of MLH1
150
occurs as a result of promoter hypermethylation (Strathdee et al. 1999).
Methylation-specific PCR using bisulphite modification of DNA can be used to
examine the methylation status of the hMLHl gene in tumour DNA (this could
include tumour DNA within patient serum). Potentially, this technique provides a
surrogate measure of functional MMR. Furthermore, a recent study using a
mouse xenograft system and an HPLC based technique has demonstrated that
changes in global DNA methylation within mouse peripheral lymphocytes can be
correlated to expression of MLH1 following treatment with a demethylating agent
(Plumb et al. 2000). Potentially this could be used to monitor MLH1 expression
in patients throughout their treatment. It is not known in breast cancer if MLH1
expression is lost by promoter hypermethylation. Further work needs to be done
in breast cancer to determine the mechanism of MLH1 loss and the potential
use of acceptable surrogate markers.
In HNPCC tumours and the cell lines discussed in this thesis MLH1 expression
is completely lost. Only 6 out of a total of 64 breast cancer samples examined
had completely lost MLH1 expression. Are we observing down regulation of
MLH1 expression in breast cancer rather than loss? What effect does this have
on cellular phenotype? The answers are unknown. The relationship between levels
of MLH1 expression as detected by immunohistochemistry and the MIN+
phenotype is not known. In addition, it is not clear what the cut-off points
should be for determining prognostic risk. Further research is necessary to
clarify these points.
In ovary cancer, loss of MLH1 prior to chemotherapy is an independent
predictor for poor overall survival. Furthermore, it correlates with early stage
disease, which is in itself a good prognostic factor (Mackean et al. 1999). This
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suggests, in this tumour type at least, that loss of MLH1 does not represent a
late stage of tumour progression. In gastric cancer microsatellite instability is
associated with a poor prognosis (Choi et al. 2000) and in endometrioid cancers it is
associated with improved survival (Maxwell et al. 2001). In both sporadic and HNPCC
colonic carcinomas microsatellite instability correlates with an improved prognosis
(Bubb et al. 1996, Elsaleh et al. 2000). Furthermore, patients who have MSI positive
tumours appear to have a greater benefit from adjuvant chemotherapy(Elsaleh et al.
2000). These contrasts between the different prognoses associated with MSI and
mismatch repair protein expression highlights the gap in our understanding of how
defective mismatch repair ultimately effects genome stability. In addition it suggests
that there may be a tissue specific response to the effects of MSI. It is possible that there
are different underlying mutations or mechanisms of mismatch repair inactivation
which may act to moderate or intensify tumour progression depending on the tumour
type. Each tumour has a different genetic background and the expression and/or
activation of the downstream effectors of mismatch repair may differ depending on the
site of the tumour. It has even been suggested that the site of the tumour may be a factor
in prognosis(Paulson et al. 1996). Thus, mismatch repair deficient tumours in the colon
tend to form bulky tumours which grow rapidly into the lumen resulting in early
detection (Kuismanen et al. 1999) thereby improving survival. The impact of adjuvant
chemotherapy may be having an impact on prognosis. It is not really surprising that
MSI positive colon tumours have an improved prognosis with chemotherapy as the
drugs which are used are cytotoxic independent of the mismatch repair pathway. This is
in contrast to both breast and ovarian cancer where loss of mismatch repair results in




Consistent with other studies, p53 showed no significant prognostic value before
or after combination chemotherapy and no significant change in the levels of
protein expression (Daidone et al, 1995). No association was demonstrated between
the expression of p53 and MLH1. It should be remembered, however, that
immunohistochemistry may not be a reliable measure of p53 function, and
controversy exists as to its use in determining the value of p53 as a prognostic
factor. In the light of recent publications it may be more appropriate to examine
for p73 expression (discussed in the Chapter 1).
Further work is necessary to elucidate the apoptotic pathways following detection
of doxorubicin induced DNA damage by the MMR system. The published data
focuses on lesions produced by methylating agents and cisplatin, there are no
studies examining the effects of doxorubicin or other topoisomerase inhibitors.
8.4. Circumvention of drug resistance
The clinical studies, together with the in vitro data, suggest that MLH1 may be
a key regulator of chemosensitivity in breast, ovarian and possibly other types of
cancer. This has implications for patient management:
Which drug?
Some drugs are not affected by MMR status in vitro, such as paclitaxel and
oxaliplatin(Fink et al. 1998; Fink et al. 1996). Choosing these agents may be more
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appropriate in patients whose tumours have lost expression of MLH1. Recently
human MMR defective cells have been shown to be hypersensitive to CCNU(1-
(2-chloroethyl)-3-cyclohexyl-nitrosurea) and to mitomycin C in a xenograft model
(Fiumicino et al. 2000). These issues require further investigation.
Inhibition of replicative bypass.
As discussed in Chapter 1 it has been suggested that loss of MMR leads to
replicative or recombinational bypass of DNA lesions giving a drug-tolerant
phenotype. Inhibition of this bypass could be used to sensitise cells. Aphidicolin,
an inhibitor of DNA polymerases, sensitises MMR-deficient cell lines to CDDP
(cis -diaminedichloroplatinum II) and MNU (a monofunctional methylating agent)
to a greater extent than their MMR-proficient counterparts. Potentially, the use of
polymerase inhibitors as modulators of drug resistance in MMR deficient cells
could be utilised in the clinic (Moreland et al. 1999).
Restoring expression of MLH1
Inducing the expression of MLH1 in drug resistant cells would reverse the drug
resistant phenotype. This has been demonstrated in the chromosome transfer
studies. In ovary and colon cancer cell lines loss of MLH1 expression is due to
methylation of the MLH1 promoter. Re-expression of MLH1 occurs in vitro and
in a xenograft murine model as a result of treatment with the demethylating
agent 2-deoxy-5-azacytidine (DAC) (Plumb et al. 2000). Re-expression of MLH1
corresponds to an increase in cisplatin sensitivity. Clinical trials of DAC in




The identification of loss of MLH1 as a specific genetic defect makes it a
potential target for gene therapy.
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8.5. Conclusions
Loss of MMR, and in particular loss of expression of MLH1 appears to be a
key factor in the development of resistance to a wide range of DNA damaging
drugs. This thesis supports a direct role for loss of MLH1 in the development
of resistance to doxorubicin. Which doxorubicin induced DNA lesion(s) MMR is
detecting is not clear. Further work is necessary to identify both the lesions
involved and the downstream events resulting in doxorubicin induced cell death.
Loss of MLH1 occurs as a result of chemotherapy in locally advanced breast
cancer and acts as a predictor of poor disease free survival. A large prospective
study based on the results presented in this thesis is under way as part of the Anglo
Celtic II Trial in breast cancer. If these results are confirmed in larger
prospective studies there will be important implications for the future choice of
drugs and treatment strategies employed in the treatment of breast cancer.
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Reduced MLHI Expression in Breast Tumors After Primary
Chemotherapy Predicts Disease-Free Survival
By HJ. Mackay, D. Cameron, M. Rahilly, M.J. Mackean, J. Paul, S.B. Kaye, and R. Brown
Purpose: Loss of function or expression of the mis¬
match repair protein MLH1 and the tumor suppressor
protein p53 have been implicated in acquired resis¬
tance to anticancer drugs. We have compared the ex¬
pression of MLHI and p53 in tumors from women with
clinically node-positive breast cancer before and after
primary (neoadjuvant) chemotherapy. Further, we
have assessed the value of these markers as predictors
of response to therapy by correlation with disease-free
survival.
Patients and Methods: Immunohisfochemistry scores
of MLHI and p53 expression were made on 36 tru-cut
prechemotherapy biopsies and 29 paired postchemo-
therapy tumor samples. The significance of the change in
scores and their correlation with disease-free survival
were evaluated by the Wilcoxon signed rank sum test
and Cox proportional hazards regression analysis, re¬
spectively.
Results: Primary chemotherapy results in a signifi¬
cant reduction in the percent of cells expressing MLHI
(P = .010). This change in MLHI expression after che¬
motherapy is strongly associated with poor disease-
free survival (P = .0025). Expression of p53 was not
significantly altered by chemotherapy. Neither MLH1
nor p53 expression before chemotherapy predicted
disease-free survival or tumor response to chemother¬
apy. Low MLH1 expression after chemotherapywas an
independent predictor of poor disease-free survival on
multivariate Cox analysis when considered with other
clinicopathologic prognostic factors.
Conclusion: Tumor cells that have reduced MLH1 ex¬
pression seem to have a survival advantage during
combined chemotherapy of locally advanced breast
cancers, which supports the hypothesis that loss of
MLHI has a role in drug resistance. MLH1 expression
after chemotherapy is an independent predictive factor
for poor disease-free survival and may, therefore, de¬
fine a group of patients with drug-resistant breast
cancer.
J Clin Oncol 18:87-93. © 2000 by American
Society of Clinical Oncology.
BREAST CANCER IS the most common malignancyamong women in the Western world. The ajority of
women present with disease localized to the breast with or
without axillary lymph node involvement.1 Despite radical
surgery, more than 50% of surgically treated patients
eventually relapse. The introduction of adjuvant treatment
(endocrine, chemo-, and radiotherapy) has resulted in a
reduction in mortality, with a 25% survival improvement at
10-year follow-up.2 Metastatic disease, however, remains
incurable, with patients becoming progressively less sensi¬
tive to systemic therapy.
Primary (neoadjuvant) chemotherapy is increasingly be¬
ing used in the treatment of primary breast cancer. Its
effectiveness in inducing tumor regression and, thus, allow¬
ing more conservative surgery (particularly avoidance of
mastectomy) is well established.3"5 Disease-free and overall
patient survival have been correlated with the clinical
response to primary chemotherapy, although results have
been conflicting.6,7 Studies have failed to predict tumor
response to primary chemotherapy using proliferation indi¬
ces, expression levels of the tumor suppressor gene p53 or
the apoptosis inhibitor BCL2, and amplification of the
oncogene c-erbB-2.S[0 Data for the MDR1 gene product
P-glycoprotein (P-gp) are conflicting,11 although coexistent
p53 and P-gp expression has been reported to be an
independent prognostic factor for short disease-free surviv¬
al.12 Overexpression of c-erbB-2 has also been reported as
an independent prognostic factor for short disease-free and
overall survival,13 although again data are conflicting.9
Several studies have suggested a role for mismatch repair
(MMR) deficiency in the development of drug resis¬
tance.1416 Loss of the MMR protein MLHI occurs in tumor
cell lines selected for resistance to methylating agents,
cisplatin, and doxorubicin.14,15 The promoter of the hMLHl
gene has recently been shown to undergo hypermethylation
in tumors and cisplatin-resistant cell lines, which correlates
with loss of MLHI expression.17,18 This may be the basis
for the high frequency of MLHI loss, rather than other
MMR proteins, observed in tumors and drug-resistant mod¬
els.14"17 MLHI-deficient tumor lines with MMR activity
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restored by chromosome transfer are more sensitive than the
MMR-deficient parental line to several clinically important
agents, including cisplatin, carboplatin, doxorubicin, etopo-
side, and thioguanine.16,19 Exposure to such agents in vitro
and in vivo results in enrichment of the MLH1-deficient
population.20,21 Loss of MMR leads to an increased rate of
frameshift mutations in DNA, which is manifested by
genetic instability at repeat sequences in DNA, giving
increase to microsatellite instability (MSI).22 Thibodeau et
al23 examined paraffin-embedded tissue from colorectal
tumors for both MLH1 and MSH2 by immunohistochem-
istry (IHC) and compared the results with detection of MSI
and MMR gene mutation analysis. They showed that loss of
immunohistochemical staining for these MMR proteins
corresponded closely with loss of function of these genes
detected by MSI.
Mutation of the tumor suppressor gene p53 is a frequent
genetic change in breast cancer.24 Although the results of
studies vary, mutant p53 is generally viewed as an indicator
of poor prognosis in breast cancer.25,26 In view of the central
role of wild type p53 in cell cycle control and induction of
apoptosis,27,28 mutation of p53 may play a role in the
development of resistance to chemotherapy. An in vitro
study examining chemosensitivity in human breast cancer
specimens reported a correlation between mutant p53 pro¬
tein expression and enhanced chemoresistance.29 These
findings, however, have not been supported in clinical
studies, with mutant p53 failing to act as an indicator of
response to chemotherapy.8,9,30
The aim of the present study was to investigate MLH1
and p53 expression in sporadic breast cancer. The study
focused on these two proteins because of the limited amount
of biopsy material available for analysis, especially before
treatment, and previous in vitro studies implicating their
importance in drug resistance.16,17,29 Using samples ob¬
tained before and after neoadjuvant chemotherapy, we have
examined the effect of chemotherapy on MLH1 and p53
expression and have assessed the correlation of these
markers with clinical outcome.
PATIENTS AND METHODS
Patients
Archival paraffin-embedded material was obtained from 36 patients
treated with neoadjuvant chemotherapy for primary breast cancer
between 1993 and 1997. Samples were obtained from either the
Beatson Oncology Center (Glasgow, United Kingdom) or the Western
General Hospital (Edinburgh, United Kingdom). Samples consisted of
a tru-cut biopsy taken at the time of diagnosis and tumor taken at
surgery after chemotherapy. Of the 36 patients, paired samples were
available for 29; for seven patients, paired biologic determinants were
not available because of the few or no tumor cells present in their
samples. Median age of the patients was 47 years (range, 26 to 66
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Abbreviations: UK, unknown; ER, estrogen receptor; CR, complete response;
PR, partial response; SD, stable disease; PD, progressive disease.
years). The median maximum tumor diameter at diagnosis was 6 cm
(range, 2.9 to 15 cm). Other patient characteristics are as listed in Table
1. Eleven patients received continuous-infusion fluorouracil 200 mg/
m2/d, doxorubicin 50 mg/m2, and cyclophosphamide 600 mg/m2 every
3 weeks; 16 patients received doxorubicin 20 to 30 mg/m2 /wk and
continuous-infusion fluorouracil 200 mg/m2/d; and nine patients re¬
ceived epirubicin 50 mg/m2 and cisplatin 60 mg/m2 three times weekly
and continuous-infusion fluorouracil 200 mg/m2/d. All patients com¬
pleted at least 9 weeks of treatment before the repeat biopsy at surgery.
Radiotherapy was administered according to local practice after both
chemotherapy and definitive surgery. Those who were estrogen recep¬
tor-positive were placed on tamoxifen. Response was assessed by
bidimensional tumor measurement, obtained retrospectively from pa¬
tients' case records, evaluated according to International Union Against
Cancer criteria, and maintained over at least 4 weeks.3' Median
follow-up was 41 months (range, 30 to 66 months).
Immunohistochemistry
IHC was performed on histology sections taken from the tru-cut
biopsy and mastectomy specimens. All samples were formalin-fixed
and paraffin-embedded. Mouse monoclonal antibodies G168-15 (1/100
dilution; PharMingen, Oxford, United Kingdom) and DO-1 (1/200
dilution; Oncogene Sciences, Cambridge, United Kingdom) were used
to detect MLH1 and p53, respectively, using a peroxidase-labeled
streptavidin-biotin technique.32 Slides were deparaffinized in Histo-
clear (Fischer Scientific Ltd, Loughborough, United Kingdom) then
rehydrated through graded alcohols and water. Removal of endogenous
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peroxidase activity was achieved by incubation in 0.1% hydrogen
peroxide for 20 minutes. Sections were immersed in 10 mmol/L sodium
tricitrate buffer pH6, subjected to heat-induced antigen retrieval by
microwaving for 15 minutes, and then cooled for 20 minutes. The
commercially available Vectastain Elite ABC Kit (Vector Laboratories
Burlingame, CA) was used to detect the antigen. Sections were lightly
counterstained with hematoxylin. Internal controls were obtained for
each slide by omitting the primary antibody. For MLH1, external
controls included A2780 cells (positive control for MLH1 and negative
control for p53) and A2780/CP70 cells (negative control forMLH1 and
positive control for p53).14,33 Two slides per patient sample were
immunostained in separate runs. Slides were scored by a consultant
■pathologist using light microscopy. A score of 0 to 3 for stain intensity
was assigned: no staining = 0; weakly positive = 1; moderately
positive = 2; and strongly positive = 3. Percentage staining was
assessed both as a percentage figure and according to the scoring
system: 0 = 0% to 5%; 1 = 5% to 20%; 2 = 20% to 80%; and 3 = 80%
to 100%. A combined immunohistochemical score (H-score) was
achieved by multiplying the percent by the intensity score.34 Both
immunostaining and scoring were blinded to clinical outcome.
mStatistical Methods
Variables taken into account for statistical analysis included estrogen
—receptor status, age, menopausal status, size, grade, nodal status, and
■esponse to chemotherapy. All information was obtained retrospec¬
tively from patient records. The within-patient comparison of MLH1
eind p53 scores before and after chemotherapy was assessed using the
•Vilcoxon signed rank sum test. An association between the p53 and
V1LH1 scores was determined using Spearman rank correlation coef-
icient. The univariate examination of the association between disease-
ree survival and p53, MLH1, and clinical factors was made using the
lox regression analysis. The likelihood ratio P value is quoted. The
nultivariate analysis of factors associated with disease-free survival
fas also conducted using Cox (multiple) regression techniques and a
brward selection procedure (P to enter = .05, P to remove = .10)
RESULTS
-Changes in MLH1 and p53 Expression in Response
to Chemotherapy
Paired breast tumor samples from the same patient before
and after neoadjuvant chemotherapy were evaluated for
MLH1 immunohistochemical (IHC) staining. An example
ofMLH1 immunohistochemical analysis of paired samples
-before and after chemotherapy is shown in Fig 1. There was
a significant reduction in the percent of cells expressing
Ml,HI after neoadjuvant chemotherapy (P = .010, n = 28).
■Matched patient percent MLH1 H-scores before and after
chemotherapy are shown in Fig 2. The median percent
before and after chemotherapy was 83% and 75%, respec¬
tively. Furthermore, there was a reduction in the intensity of
-staining within cells seen after chemotherapy (P = .068,
t = 28). Sixty-one percent of patients had immunostain
~
intensity scores of 2 or greater before treatment compared
P^h 36% after chemotherapy. The overall median MLH1
- H-score (multiplying percentage and intensity) after chemo-
Fig 1. MIH1 immunohistochemishy. (A) Tru-Cut biopsy before chemo¬
therapy; positive for MLH1 immunostaining (brown). (B) Mastectomy speci¬
men with low MLH1 immunostaining. Both sections were counterstained with
hematoxylin (blue). Samples are taken from same patient before and after
fluorouracil, doxorubicin, and cyclophosphamide chemotherapy (disease-
free survival, 5 months). Magnification, x200.
therapy was significantly lower than before chemotherapy
(P = .036, n = 28). A subgroup analysis by chemotherapy
regimen also showed a reduction in median MLH1 after
chemotherapy.
There was no statistically significant correlation between
percent or intensity of MLH1 and p53 staining before or
after chemotherapy. There was no significant difference
Pre Post Pre Post Pre Post
Chemotherapy
Fig 2. Paired MIH1 scores in breast cancer samples before and after
chemotherapy. Percent H-scores are shown for each biopsy sample. Scores





































































Fig 3. Kaplan-Meier survival
curves. MLH1 H-scores before chemo¬
therapy (A, C) and after chemother¬
apy (B, D). (A) and (B) show percent
MLH 1 -positive; ( ) > 80%, (
) < 80%. (C) and (D) show MLH1
intensity; ( ] scores of 2 to 3,
( ) scores of 0 to 1.
N=11
N=18 J
10 20 30 40 50 60 70
Time (months)
between the p53 H-scores after chemotherapy. Subgroup
analysis of p53 H-scores by individual chemotherapy regi¬
men also failed to show any difference before and after
chemotherapy.
Univariate and Multivariate Analysis
There was a highly significant correlation between poor
disease-free survival and a low level of MLH1 expression,
as expressed by percentage staining (P = .0022, n = 28) or
intensity of staining within cells (P = .015, n = 28)
obtained in the postchemotherapy samples using Cox re¬
gression analysis. In addition, the difference between the
pre- and postchemotherapy scores was found to correlate
with a poor disease-free survival (P = .0025, n = 27). The
prechemotherapy MLH1 and p53 H-scores did not predict
for response to primary chemotherapy. Furthermore, neither
the prechemotherapy MLH1 percent (P = .32, n = 33) nor
intensity (P = .38, n = 33) predicted for disease-free
survival. Likewise, prechemotherapy p53 percent (P = .47,
n = 31) and intensity (P = .34, n = 31) did not predict for
disease-free survival or postchemotherapy p53 score (P =
.12, n = 29). Figure 3 shows Kaplan-Meier survival curves
for MLH1 percent and intensity IHC scores before and after
chemotherapy.
Analysis of individual patients with low MLH1 expres¬
sion (before or after chemotherapy) has shown they have a
short disease-free survival. Three patients had completely
lost expression of MLH1 after chemotherapy, and they
relapsed at 4, 8, and 15 months, respectively. Two patients
had significantly low expression of MLH1 before chemo¬
therapy (0% and 10% of cells positive for immunostaining);
these patients progressed at 12 months and 6 weeks,
respectively. Of the seven patients for whom paired samples
were unavailable, one achieved a complete response (pre¬
chemotherapy sample 80% MLH 1-positive) and remains in
remission at 49 months. Of the remaining six patients, no
clear pattern emerged and the distribution of prechemo¬
therapy MLH1 scores was indistinguishable from the oth¬
ers. The failure to produce a postchemotherapy MLH1 score
was because of poor sample quality.
A univariate analysis of clinical characteristics showed an
association between poor disease-free survival and young
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n = 34), and poor response to chemotherapy (P = .005, n =
33). The associations between disease-free survival and
estrogen receptor status, nodal stage, tumor grade, and
pathologic nodal status after chemotherapy were not statis¬
tically significant at the 20% level. A forward stepwise
multivariate analysis was conducted using the statistically
significant clinical features along with MLH1 intensity,
percentage staining, combined IHC score after chemother¬
apy, and change in IHC score (before and after). This
identified percentage staining (P = .019), age (P < .001),
response to chemotherapy (P = .001), and menopausal
status (P = .041) as independent prognostic factors (n = 27).
DISCUSSION
Neoadjuvant treatment provides a system to study in vivo
the effect of chemotherapy on the proportion of cells
expressing given genes in the initial biopsy compared with
{the tumor after chemotherapy from the same patient. This
provides an ideal opportunity to study clinical drug resis¬
tance. A small number of studies have examined the impact
pf neoadjuvant chemotherapy on biologic marker expres¬
sion, with changes observed in proliferation indices, prolif¬
erating cell nuclear antigen, expression of P-gp, and epider¬
mal growth factor receptor.35"37 However, a consistent
picture correlating these markers with clinical drug resis¬
tance has not yet emerged. There have been numerous in
vitro studies linking the loss of DNA MMR to dmg
tesistance,14-16 but little is known about its clinical signifi¬
cance. We have shown, for the first time, that combined
hemotherapy results in loss of MLH1 expression, and that
this is a poor prognostic indicator in patients receiving
neoadjuvant treatment for locally advanced breast cancer.
Loss of MLH1 expression seems to act independently of the
— Other prognostic factors in this study and to be a good
predictor of poor disease-free survival.
H These observations are consistent with the hypothesis that
tumor cells with reduced MLH1 have a survival advantage
(luring chemotherapy and also support the contention that
loss of MLH1 plays a role in drug resistance. MLH1
expression after chemotherapy, but not before chemother¬
apy, is an independent predictive factor for poor disease-
gpee survival and may, therefore, define a group of patients
Awith drug-resistant breast cancer. Expression analysis be¬
fore chemotherapy may fail to predict disease-free survival
^tiecause of an inability to identify resistant subpopulations
ftat are more readily identifiable after chemotherapy. This
^olds the caveat that postchcmotherapy biopsy represents
{.residual and not necessarily clinically resistant disease.
| It is conceivable that, rather than causing drug resistance,
='|fs of MLH1 is a marker for other changes that result in a
Rore aggressive tumor phenotype. However, in vitro studies
show that restoration of MMR in deficient cells restores
drug sensitivity,16'19 strongly arguing that MMR can have a
direct role in drug sensitivity and, therefore, potentially in
response of patients to chemotherapy. Acquisition of mic-
rosatellite instability phenotype, a marker for loss ofMMR,
has previously been shown to correlate with reduced sur¬
vival and poor disease prognosis in breast cancer.38 Con¬
versely, a microsatellite phenotype correlates with good
prognosis in colon cancer.39 These differences may reflect
the different impact of a mutator phenotype on tumor
progression (in the case of colon cancer) versus lapk of
MMR on drug sensitivity (in the case of breast cancer).
How MMR deficiency could lead to the development of
drug resistance is not yet fully understood. The MMR
protein MutSa (a heterodimer of MSH2 and MSH6) recog¬
nizes and binds to sites of DNA damage, such as O6-
methylguanine and 1,2-cisplatin intrastrand crosslinks, and
is proposed to lead to recruitment of MutLa (a heterodimer
of MLH1 and PMS2 Oe-methylguanine) into the com¬
plex.40'41 This has been suggested to lead to either futile
rounds of DNA repair42 or replication stalling14 and activa¬
tion of an apoptotic pathway. For topoisomerase II inhibi¬
tors (such as doxorubicin), MMR proteins may serve as a
detector of the cleavable complex produced by the binding
of the dmg to topoisomerase II.43 Alternatively, doxorubicin
is known to participate in redox cycling reactions that
produce DNA damage including crosslinks44 that may be
recognized by MMR.
We chose to examine MLH1 expression specifically as this
is the MMR protein that has been shown in vitro to be most
frequently lost as a result of serial exposure to chemotherapy.14
An increase in ovarian tumors immunologically negative for
MLH1 is observed in samples taken after chemotherapy
compared with untreated tumors.14 The frequent loss ofMLH1
may be because of the higher probability of inactivation by
methylation of the promoter of this gene.1718 Patients in the
present study received regimens containing either doxorubicin
or cisplatin, drugs exhibiting resistance in vitro associated with
loss of MLH1 expression.14-17
Consistent with other studies,36 p53 showed no signifi¬
cant prognostic value before or after combination chemo¬
therapy and no significant change in the levels of protein
expression. It should be stated, however, that IHC may not
be a reliable measure of p53 function, and controversy
exists as to its use in determining the value of p53 as a
prognostic factor. We could find no association between
MLH1 and p53 expression as assessed by IHC.
Our results should be viewed with caution because of the
relatively small patient numbers, different chemotherapy
regimens, and the use of a selected patient population.
However, this study does demonstrate, for the first time,
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clear evidence for loss ofMLH1 as a result of chemotherapy
in matched pairs of breast tumor samples. Further, it
suggests that loss of expression of MLH1 is an important
prognostic factor in predicting disease-free survival in this
group of patients. Large prospective studies are now neces¬
sary to further validate these observations. If loss of MLH1
is confirmed as being involved in clinical drug resistance in
breast cancer, this opens up a number of possibilities for
improving treatment results, including the development of
agents that may be active in MMR-deficient cells or that
may be capable of reversal of resistance.
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Dependence on RAD52 and RAD1 for anticancer drug resistance
mediated by inactivation of mismatch repair genes
Stephen T. Durant, Melanie M. Morris, Maureen Illand, Helen J. McKay,
Carol McCormick, Gillian L. Hirst, Rhona H. Borts* and Robert Brown
Mismatch repair (MMR) proteins repair mispaired DMA
bases and have an important role in maintaining the
integrity of the genome [1]. Loss of MMR has been
correlated with resistance to a variety of DNA-damaging
agents, including many anticancer drugs [2], How loss
of MMR leads to resistance is not understood, but is
proposed to be due to loss of futile MMR activity and/or
replication stalling [3,41. We report that inactivation of
MMR genes (MLH1, MLH2, MSH2, MSH3, MSH6, but not
PMS1) in isogenic strains of Saccharomyces cerevisiae
led to increased resistance to the anticancer drugs
cisplatin, carboplatin and doxorubicin, but had no effect
on sensitivity to ultraviolet C (UVC) radiation. Sensitivity
to cisplatin and doxorubicin was increased in mlhl
mutant strains when the MLH1 gene was reintroduced,
demonstrating a direct involvement of MMR proteins in
sensitivity to these DNA-damaging agents. Inactivation
of MLH1, MLH2 or MSH2 had no significant effect,
however, on drug sensitivities in the rad52 or rad1
mutant strains that are defective in mitotic
recombination and removing unpaired DNA single
strands. We propose a model whereby MMR proteins -
in addition to their role in DNA-damage recognition -
decrease adduct tolerance during DNA replication by
) modulating the levels of recombination-dependentbypass. This hypothesis is supported by the finding that,
in human ovarian tumour cells, loss of hMLH1
correlated with acquisition of cisplatin resistance
and increased cisplatin-induced sister chromatid
exchange, both of which were reversed by restoration
of hMLH1 expression.
Addresses: CRC Department of Medical Oncology, CRC Beatson
laboratories, Glasgow G61 1BD, UK. 'Yeast Genetics, Institute for
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Results and discussion
"^e examined drug sensitivities of isogenic haploid strains of
'■ cerevisiae that had specific MMR genes disrupted
(Table 1; for a review of the biochemistry and genetics of
eukaryotic MMR, see [5]). Disruption of the MutS homo-
logues MSH2, MSH3 and MSH6 and the MutL homologues
MLH1 and MLH2 (but not PMS1) conferred a significant
increase in resistance to cisplatin and carboplatin compared
with the wild type (Table 1, Figure la). Genetic inactiva¬
tion of MLH1, MSH2, MSH3 and MSH6 also led to
increased resistance to doxorubicin. None of the MMR
mutants, however, showed any significant increase in resis¬
tance or sensitivity to UVC radiation (Table 1). Transforma¬
tion of the MLH1 gene back into the mlhl mutant strain
(mlhl + pMLHl) led to increased sensitivity to cisplatin and
doxorubicin compared with vector-alone controls
{mlhl + vector; Table 1). Together, these results demon¬
strate a direct role of MMR proteins in cisplatin, carboplatin
and doxorubicin sensitivity.
Loss ofMMR usually leads to increased gene mutation rates,
leading to a mutator phenotype [6,7]. We examined the
MMR mutant strains used for mutant frequency (Table 1)
and mutation rate [8]. The wild-type strain had a mutation
rate of 3.7 x 10 s per viable cell, mlhZ mutants a rate of
6.7 x 10-8 per viable cell and pmsl mutants a rate of
8.7 X ICR6 per viable cell. The drug-resistance phenotype of
mlh2 mutants and absence of it in pmsl mutants suggests that
Mlh2p, but not Pmslp, has a role in processing of the type of
damage induced by these agents. The mutator phenotype in
pmsl but not in mlh2 mutants argues that loss ofMMR activ¬
ity per se (or at least MMR activity requiring Pmslp) need
not lead to resistance, and that acquisition of drug resistance
is not due to the mutator phenotype of these strains. 1
The S. cerevisiae RAD52 gene is involved in meiotic and
mitotic recombination [9]. RAD52 inactivation led to
increased sensitivity to cisplatin and UV radiation
(Table 1). Inactivation ofMLH1, MLH2 orMSH2 in a rad52
mutant strain had no significant effect on sensitivity to cis¬
platin, carboplatin or UV radiation (Table 1, Figure lb).
Thus, inactivation of RAD52 leads to loss of the resistance
mediated by MMR gene inactivation and a sensitisation of
the yeast to these agents. This suggests that drug resistance
mediated by loss of MMR is dependent on RadS2p activity
and implicates a recombination-dependent process in
damage tolerance. Possible models for recombinational
bypass of lesions during DNA replication, that would be
Rad52p dependent, have been proposed previously [10].
Inactivation of RAD1 also led to increased sensitivity to
cisplatin, carboplatin and UV radiation (Table 1). The
52 Current Biology, Vol 9 No 1
Table 1
Sensitivities of MMR mutants to anti-cancer drugs and UV radiation.
Genotype Strain IC90 RF IC90 RF IC90 RF IC90 RF Mutant
Cisplatin (mM) Carboplatin (mM) Doxorubicin (mM) UV (J/m2) frequency
Wild type 2096-1B 1 1 13 1 70 1 170 1 1.6X10-6
msh2 RHB 2348 1.7 1.7* 20 1.5* 370 5.3* 210 1.2 2.5x10-6
msh3 RHB 2347 1.8 1.7* 28 2.2* 310 4.4* 130 0.8 n.d.
msh6 NHT 1 73 1.7 1.6* 29 2.2* 420 6* 190 1.1 n.d.
mlhl RBT 311 1.5 1.4* 36 2.8* 150 2.1* 150 0.9 4.7 x 10-5
mlh2 RBT324 2 2* 40 3.1* n.d. - 150 0.9 9.6 x 10"7
pmsl RBT 269 1.1 1.1 10 0.7 n.d. - 140 0.8 8.7x10-5
mlh 1 + vector RBT311 :v 1.6 1.6* 29 2.2* 120 1.7* n.d. - n.d.
mlhl + pMLH1 RBT311 :mlh1 0.5 0.5* 10 0.8 30 0.4* n.d. - n.d.
rad52 RHB 2692 0.7 0.7* 13 1 n.d. _ 70 0.4* n.d.
rad52/msh2 RHB 2700 0.7 0.7 13 1 n.d. - 70 0.4 n.d.
rad52/mlh 1 RHB 2698 0.5 0.5 12 0.9 n.d. - 80 0.5 n.d.
rad52lmlh2 RHB 2699 0.6 0.6 13 1 n.d. - 100 0.6 n.d.
radl RBT 302 0.6 0.6* 7 0.5* n.d. - 10 0.06* n.d.
rad1lmsh2 RHB 2694 0.6 0.6 7.5 0.6 n.d. - 13 0.08 n.d.
rad1/mlh1 RHB 2693 0.7 0.7 8 0.6 n.d. - 11 0.06 n.d.
rad1/mlh2 RHB 2695 0.6 0.6 8 0.6 n.d. - 11 0.06 n.d.
All strains are isogenic derivatives of a Mata wild-type strain. The
construction of all of the mismatch-repair-deficient strains except mlh2
has been described [22], MLH2 was deleted using an oligonucleotide-
based KANMX disruption cassette. RAD52 was disrupted with LEU2
using plasmid pMS20 obtained from D. Schild [23]. RAD1 was
deleted using a LEU2 disruption/deletion plasmid obtained from
R. Keil [24], IC90, concentration of drug inducing a 90% reduction in
RAD1 gene in S. cerevisiae is involved in nucleotide exci¬
sion repair (NER), but has also been implicated in mitotic
recombination [11]. Purified Radlp interacts with DNA
bubble structures, is required for the endonucleolytic
cleavage that removes 3' single-stranded DNA ends [11],
and is also required for removal of non-homologous ends
during recombination [12]. These are activities that could
be required for recombination-dependent DNA-damage
bypass by removing bases to allow initiation of replication
after bypass [13]. Inactivation of MLH1, MLHZ or MSH2
had no significant effect on cisplatin or carboplatin sensi¬
tivities in a radl mutant strain (Table 1, Figure lc). These
observations are consistent with Radlp being necessary
for increased damage bypass.
We propose a model whereby loss of MMR proteins can
increase RAD52/RAD1-dependent recombinational bypass
of adducts (see Figure 2). Treatment of cells with cisplatin
and carboplatin induces predominantly 1,2 intrastrand
DNA crosslinks which is believed to be the major cytotoxic
lesion [14], although a role for the minor lesions cannot be
excluded. The 1,2 intrastrand crosslink induced by cis¬
platin and carboplatin is poorly repaired, either due to not
being recognised by NER [15] or by inhibition of repair,
for instance by damage-recognition proteins [16]. Consis¬
tent with this, inactivation of RAD1 in S. cerevisiae did not
give the extreme hypersensitivity to cisplatin observed for
UV radiation (Table 1). Persistent or non-repaired DNA
surviving fraction. RF, resistance factor relative to the wild-type strain.
Those marked with an asterisk are significantly different in drug
sensitivity from the wild-type strain or the corresponding single mutant,
as assessed by a two-tailed Student's f-test at 1.5 mM cisplatin or
15 mM carboplatin. Mutant frequency, the number of L-canavanine-
resistant colonies per 106 colony forming units; n.d., not determined.
lesions could lead to a cytotoxic signal being generated
during DNA replication. The heterodimer of Msh2p and
Msh6p— hMutSa—recognises 1,2 cisplatin crosslinks in
a complementary duplex DNA and with greater affinity if
the platinated guanine residues are opposite non-comple¬
mentary bases [17]. Bypass of cisplatin DNA lesions during
DNA replication has been shown in cisplatin-resistant
human cells which correlates with defects in MMR [18].
The mechanisms leading to bypass are largely unknown,
but possibilities include recombinational mechanisms, as
well as trans-lesion DNA synthesis. It has been shown that
MMR proteins can affect levels of homologous recombina¬
tion in yeast [19,20]. Alternatively, MMR proteins recog¬
nising cisplatin adducts may lead to inefficient MMR,
which competes with recombinational bypass of the lesion.
If RAD52/RAD1-dependent recombinational bypass of
DNA adducts occurs during replication, then inhibition of,
or competition with, either initiation or progression of this
process by MMR proteins will lead to sensitivity. Con¬
versely, loss of MMR proteins will reduce the probability
of lethal signals being generated during replication by
increasing adduct bypass, leading to resistance. Consistent
with DNA replication being necessary for MMR-depen-
dent drug sensitivity, we observed a significantly increased
resistance of cells exposed to cisplatin during the stationary
phase of growth compared with exponentially growing
cells — for an exponentially growing wild-type strain of S.
cerevisiae, the concentration of cisplatin that results in 90%
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Drug toxicity was measured by exposing exponentially growing cells in
liquid culture for 24 h to cisplatin, plating out 400 cells onto YPD
medium and allowing colony formation. Values shown are the means of
multiple independent experiments representing at least 15 repeat
values at each drug concentration and using independent clonal
isolates. Curves through data points represent second order linear
regression. Error bars represent 99°/o confidence limits.
inhibition of clonal growth (ID90) is 1.0 mM, whereas that
of stationary cells is 1.8 mM. On the other hand, the cis¬
platin sensitivity of msh2 mutants (ID90 = 1.7 mM) is not
affected by growth phase.
To examine the potential relevance of the observations
made in S. cerevisiae to how tumours may acquire resistance
to these chemotherapeutic drugs, we examined cisplatin
sensitivities in a matched set of human ovarian tumour cell
lines. If recombinational bypass of DNA adducts during
DNA replication occurred, this would be manifested by a
sister chromatid exchange (SCE). A2780 is a human ovarian
carcinoma cell line derived from an untreated patient,
whereas A2780/cp70 is an in-vitro-derived cisplatin-resistant
derivative that has lost MMR activity due to loss of hMLHl
expression [4]. We introduced a human chromosome 3 con¬
taining a wild-type hMLHl gene into the A2780/cp70 line
and showed restoration ofMlhlp expression, MMR activity
and partial restoration of cisplatin sensitivity (Table 2). We
also observed increased resistance of A2780/cp70 to doxoru¬
bicin and the methylating agent N-nitrosomethylurea
(MNU) and restoration of sensitivity of the chromosome 3
transfers (Table 2). The restoration of drug sensitivities in
the A2780/cp70/ch3 line supports a direct role for MLH1 in
cell death induced by these drugs in these ovarian cells.
Furthermore, as shown in Table 2, A2780/cp70 cells, which
Table 2











per cell per chromosome per cell per chromosome
A2780 + 0.2 10 15 1.2 0.026 6.3 0.14
A2780/cp70 - 0.79 65 25 1.5 0.034 16.2 0.37
A2780/cp70/ch2 - 0.65 56 25 2.0 0.044 18.2 0.4
A2780/cp70/ch3 + 0.21 12 16 1.0 0.022 9.6 0.21
A2780/cp70/ch3 and A2780/cp70/ch2 are derivatives of
A2780/cp70 that have, respectively, chromosome 3 or 2 introduced
by microcell-mediated chromosome transfer. MMR status was
determined by in vitro assays using plasmid substrates with defined
mismatches (P. Karran and O. Humphries, personal communication).
Western analysis with hMlh 1 -specific antibodies (data not shown)
indicated that MMR+ lines express hMlh 1, whereas MMR- lines do
not. IC50 values are the concentrations of MNU, cisplatin or
doxorubicin necessary to reduce the surviving fraction of cells by 50%.
Cells were treated with MNU after depletion of Oe-alkyltransferase
are the mean of multiple independent clonogenic assays. A2780 and
A2780/cp70/ch3 are significantly more sensitive to MNU, cisplatin and
doxorubicin than A2780/cp70 and A2780/cp70/ch2 as determined by
two-tailed Student's t-test (p < 0.01). *The number of SCEs in
exponentially growing cells that were either untreated or treated with
10 pM cisplatin for 1 h. SCEs were quantified by Hoechst staining,
followed by Giemsa staining of 5-bromo-2'-deoxyuridine (BrdU)-
labelled metaphase spreads. At least 40 metaphases were scored.
A2780 and A2780/cp70/ch3 have significantly less SCEs after
cisplatin treatment than A2780/cp70 and A2780/cp70/ch2, as
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Model of MMR modulation of recombination bypass affecting drug
sensitivity. Certain types of dna damage induced by chemotherapeutic
drugs such as cisplatin are poorly repaired and may persist in the
genome. We propose that signals are generated during dna replication
of this unrepaired damage that could lead to cell death, but have the
potential to be bypassed in a RAD52/RAD1 -dependent manner that will
lead to damage tolerance and cell survival. This recombinational bypass
can be inhibited by MMR expression. Thus, loss of MMR leads to
increased drug resistance because of increased bypass.
have lost Mlhlp expression, have a higher level of SCEs
induced by cisplatin than the MMR-proficient parental
A2780 line. Restoration of Mlhlp expression in the
A2780/cp70/ch3 line reduced the level of SCEs induced,
whereas introduction of chromosome 2 (A2780/cp70/ch2),
which does not restore MMR activity, had no effect. These
observations are consistent with a chromatid exchange
mechanism being modulated by MMR and with the
hypothesis that recombination bypass of cisplatin adducts
leads to damage tolerance in MMR-defective tumours.
The data presented in yeast and mammalian cells provide
evidence for MMR proteins directly affecting cytotoxicity
induced by cisplatin, carboplatin and doxorubicin.
Although loss of MMR is associated with methylation tol¬
erance in mammalian cells, increased tolerance to methy-
lating agents has not been observed in yeast strains
defective in MMR genes, except for msh5 mutants [21].
This may imply that 06-mcthyl guanine induces toxicity
by a different mechanism or that this lesion is processed
by other repair pathways in yeast masking any effects of
MMR on sensitivity to methylating agents. The yeast
strains described in the present study will provide a means
to examine other anticancer agents and platinum ana¬
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Original Article
A Pilot Study of Continuous Infusional 5-Fluorouracil,
Doxorubicin and Cyclophosphamide in Breast
Cancer
H. J. Mackay1, D. Bissett2, C. Twelves1 and P. A. Vasey1
'Beatson Oncology Centre, Glasgow and 2Aberdeen Royal Infirmary, Aberdeen, UK
Abstract. The purpose of this study was to evaluate the toxicity and activity of continuous infusional 5-
fluorouracil (5-FU) given at three dose levels in combination with cyclophosphamide and doxorubicin (FAC) in
women with breast cancer.
Thirty-nine patients with either primary tumours >3 cm prior to surgery (n = 24) or metastatic disease (n = 15)
received cyclophosphamide 600 mg/m2 and doxorubicin 50 mg/m2 as an intravenous bolus every 3 weeks for six
courses. Continuous infusional 5-FU was delivered via a central venous line for a maximum of 18 weeks at dose
levels of 100 mg/m2 per day (n - 6), 150 mg/m2 per day (n = 3) and 200 mg/m2 per day (n = 30).
At the 200 mg/m2 per day dose level, 36% of patients required dose delays and 23% dose reductions; there was
one death due to neutropenic sepsis. Hickman line complications occurred at all dose levels, particularly
thrombosis (18%) and infection (33%). The response rate was 62% (95% confidence interval (CI) 32-84) for
metastatic disease, including five complete responses (CRs). The response rate for primary tumours prior to
surgery was 81% (95% CI 57-95) including six clinical CRs.
Infusional FAC is an active regimen and has an acceptable toxicity profile. It does not, however, appear to offer
any significant advantage over other chemotherapy regimens. This study does not support the further evaluation of
infusional 5-FU at these doses in combination with doxorubicin and cyclophosphamide.
Keywords: Breast neoplasms; Chemotherapy; Infusional 5-fluorouracil
Introduction
The combination of bolus 5-fluorouracil (5-FU),
doxorubicin and cyclophosphamide is a standard
regimen, with proven activity in the treatment of
breast cancer. As primary therapy in women with
large tumours (>3 cm), response rates of 70%-87%
have been reported [1]; in metastatic disease, the
reported response rate ranges between 30% and 70%
[2], Attempts have been made to optimize this
regimen by dose escalation with colony stimulating
factor support [2]. An alternative approach in view of
the short half-life and S-phase specificity of 5-FU is to
administer it as a continuous infusion [3j.
Phase II studies in solid tumours have demonstrated
^activity for continuous infusional 5-FU both as a
single agent and in combination with other drugs. In
breast cancer, single-agent studies have shown
Correspondence and offprint requests to: Dr H. J. Mackay, CRC
Department of Medical Oncology, Beatson Oncology Centre,
Alexander Stone Building, Garscube Estate, Switchback Road,
Bearsden, Glasgow G61 1BD, UK.
response rates of between 12% and 50% using doses
ranging from 150 mg/m2 per day to 500 mg/m2 per day
[4]. In some cases, patients have remained sensitive to
infusional 5-FU when they have become resistant to
bolus therapy. Higher total doses of 5-FU can be given
by continuous infusion with comparable levels of
toxicity as for conventional bolus administration.
When this study was devised there had been no
direct comparison between FAC (5-FU, doxorubicin,
cyclophosphamide) regimens using bolus 5-FU and
continuous infusion. The first aim of the study was to
identify the dose of continuous infusional 5-FU that
could be given with standard doses of adriamycin and
cyclophosphamide. The second aim was to make a
preliminary evaluation of the activity of infusional
FAC. If these data were sufficiently encouraging, a
randomized comparison of bolus and infusional FAC
was planned. Based on previously published response
data for bolus FAC, our criterion for proceeding to a
larger trial was a minimum overall response rate for




Between January 1994 and May 1996, a total of 39
patients were treated in this pilot study. Those who
had histologically confirmed breast carcinoma with
either large primary (>3 cm) tumours or metastatic
disease were eligible if they had an ECOG
performance status of 0 or 1 and were aged between
18 and 70 years. For patients with metastatic disease,
previous adjuvant chemotherapy was allowed pro¬
vided it was completed at least 12 months prior to
study entry and did not include an anthracycline; prior
hormonal therapy and radiotherapy were permitted.
Patients had to be deemed able to manage a central
venous line and an ambulatory intravenous infusion
pump. Written informed consent was obtained in
accordance with local ethics committee guidelines.
Initial staging investigations included clinical
examination with bidimensional tumour measurement
(if appropriate), full blood count, plasma biochem¬
istry, serum liver function tests and chest radiography.
Cardiac assessment was by electrocardiogram and
echocardiogram. A bone scan and a liver ultrasound
examination were performed in patients with meta¬
static disease or when clinically indicated. Primary
tumours were assessed by clinical measurement and
mammography was repeated at the end of treatment.
Treatment
All patients received bolus cyclophosphamide 600
mg/m2 and doxorubicin 50 mg/m2 intravenously
every 3 weeks for a maximum of six courses. In
addition, 5-FU was administered as a continuous
infusion via a Hickman line using a Walkmed
portable infusion pump (Medfusion Incorporated)
for 18 weeks. The dose of 5-FU was 100 mg/m2 per
day in the first cohort of patients. Provided that dose-
limiting toxicities (e.g. complicated or prolonged
grade 4 myelosuppression, grade 3/4 stomatitis or
diarrhoea) were present in <2/6 patients, it was
planned that the 5-FU dose would be increased to 150
mg/m2 per day and then to 200 mg/m2 per day in
successive cohorts.
A double-lumen Hickman line was inserted into the
superior vena cava under radiographic screening with
antibiotic cover (vancomycin 1 mg intravenously). At
the start of the study, patients received prophylactic
low dose warfarin (1 mg/day). Despite this, several
developed Hickman line-associated thrombosis, so
subsequent patients received full warfarin anti¬
coagulation (target international normalized ratio
(INR) 2 to 3). Patients with line-associated throm¬
boses were managed by thrombolysis using heparin
and streptokinase [5].
Patients were assessed clinically every 3 weeks and
toxicity was evaluated according to standard WHO
criteria. Responses were assessed according to UICC
criteria [6,7] and are shown with 95% confidence
intervals (CI). Patients receiving neoadjuvant therapy
underwent surgery within 4 weeks of completion of
chemotherapy.
Statistical Analysis
The time elapsing from the date of starting
chemotherapy to first documented treatment failure
was considered the disease-free survival and the time
to progression in patients with primary tumours and
metastatic disease respectively. Death from all causes
was taken as the endpoint for overall survival, which
was also measured from the date that chemotherapy
started. KaplanMeier estimates were used to assess
disease-free survival, time to progression and overall
survival.
Results
The clinical characteristics of all 39 patients are
shown in Tables 1 [8] and 2. Six women were treated
at the first 5-FU dose level, three at the second and 30
at the third.
Toxicity
The pattern of toxicities is shown in Table 3.
Treatment was generally well tolerated, with the
most frequent problems being related to Hickman
lines. Of the first 15 patients treated, who all received
warfarin 1 mg daily, four (26%) developed line
thromboses. Subsequent patients received full anti¬
coagulation with the aim of achieving an INR of 2-3.
In total, seven (18%) patients had Hickman line-
related thrombosis, all occurring in those whose INR
was below the target range. Fourteen (36%) women
developed line-related infection; these were mostly
minor exit site problems not resulting in disruption to
treatment.















SBR, Standardized Bloom Richardson; ER, oestrogen receptor.
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Table 3. Toxicity of infusional FAC in 39 patients
WHO grade
Dose level 1 Dose level 2 Dose level 3
1-2 3-4 1-2 3-4 1-2 3-4
Nausea and vomiting 4 1 1 2 18 2
Haematological - 3 1 2 2 27
Cutaneous - - 1 - 7 -
Mucositis 5 - 3 3 21 6
Lethargy 1 - 2 - 10 -
Diarrhoea - - 1 7 -
Conjunctivitis - - - - 5 -
Initially, three patients were treated at the first dose
level, of whom two developed complications in
relation to the Hickman lines (infection and
thrombosis not requiring discontinuation of treatment,
respectively). An additional three patients were
treated at this dose level, one of whom had a line
thrombosis but continued treatment. Four of 36 (11%)
cycles were delayed owing to incomplete recovery of
the neutrophil count by day 22.
As none of the patients at the first dose level had
dose-limiting drug-related toxicity, the dose of 5-FU
was escalated. Again there were no dose-limiting
toxicities. However, of the three patients receiving 5-
FU 150 mg/m2 per day, two had central line infections
not related to neutropenia and one had grade 3
vomiting despite prophylactic antiemetics. Only two
of 18 cycles (11%) were delayed (owing to vomiting
and line infection respectively).
Finally, the dose of 5-FU was increased to 200 mg/
m2 per day. As this was the final dose level, a total of
30 patients were treated in order to define more clearly
the pattern of toxicities and antitumour activity. In the
third cohort, 12 patients completed treatment without
delay and 11 (37%) patients had dose delays. In total,
25 of 144 cycles (17%) given were delayed. The main
toxicities were myelosuppression and mucositis, with
seven (23%) patients requiring a reduction of 5-FU
and one requiring an additional reduction of doxor¬
ubicin. There was one death secondary to neutropenic
sepsis. Ten women (33%) failed to complete the
planned treatment programme owing to: line compli¬
cations (3), non-specific malaise (4) and progressive
disease (3). Four patients developed Hickman line
thrombosis; in each case the INR was below the target
of 2 when the thrombosis developed. After the
introduction of an anticoagulation policy, only three
of 24 (13%) patients developed a line-related
thrombosis (half the previous rate).
Antitumour Activity
As the number of patients treated was relatively small
and clinical activity was a secondary endpoint,
responses were considered together for all three
dose levels. Response was evaluable only in women
receiving at least six weeks of treatment.
Of the 24 patients with large primary tumours, 21
were evaluable, with three failing to complete 6 weeks
of treatment. Seventeen (81% CI 57-95) responded,
including six clinical complete responses (CRs) and
four (19%) with stable disease. All subsequently
underwent mastectomy and axillary clearance fol¬
lowed by radiotherapy and/or tamoxifen. There were
no pathological CRs, but ten of the 17 responding
patients were axillary lymph node negative. To date,
seven patients have developed distant metastases but
there have been no locoregional recurrences. Thirteen
patients remain well. The median disease-free survival
has not been reached but 67% (standard error (SE)
10%) are estimated to be still alive and disease free at
3 years. Furthermore, the median survival has not been
reached but the estimated percentage still alive at 3
years is 63% (SE 12%).
Of the 15 women with metastatic disease, 13 were
evaluable. Eight responded (62% CI 32-84) including
five with a CR; a further two had stable disease and
three progressed through treatment. Two patients
remain in CR 28 and 31 months after treatment. The
median time to progression was 6 months (95% CI 4-
8). The median survival is 14 months (95% CI 7-21).
Those patients with stable disease on completion of
therapy progressed at 7 and 5 months.
Discussion
In this prospective pilot study, we have shown that the
combination of infusional 5-FU, doxorubicin and
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cyclophosphamide is both safe and effective in the
treatment of primary breast cancer and metastatic
disease.
Having demonstrated the safety and activity of
infusional FAC, it is important to put this in the
context of other regimens. The benefits of primary
chemotherapy have previously been clearly demon¬
strated, with response rates for conventional che¬
motherapy combinations lying between 70% and
80%, with a median time to progression of around
20 months [1,9,10]. The combination of infusional 5-
FU (200 mg/m2), epirubicin and cisplatinum (ECF)
has shown an improved response rate of 98% [11], In
women with metastatic disease, conventional anthra-
cycline-based regimens show response rates between
30% and 70% and a median survival of 9-30 months
[2], Other continuous infusional 5-FU regimens in
combination with doxorubicin [12], epirubicin and
cisplatinum/carboplatin [13,14] give higher response
rates (76% and 84% respectively) but median survival
figures are similar. Although comparisons of different
series are subject to criticism, it appears that this
infusional FAC regimen offers no advantage over the
use of existing drug combinations. The disparity
between this combination and other infusional 5-FU
regimens may be due to the inclusion of lower 5-FU
doses, smaller patient numbers, patient selection and,
in the case of those with metastatic disease, the level
of pretreatment.
The toxicity profile of this study was dominated
by Hickman line complications. The 18% level of
line-related thromboses was significantly higher than
that of approximately 10% in other studies [4,11-
13], This highlights the importance of dedicated
specialist nursing backup and careful anticoagula¬
tion. Lokich et al. [3] established that 5-FU could be
given safely over prolonged periods in doses up to
300 mg/m2, with plantar-palmar syndrome and
mucositis replacing myelosuppression as the dose-
limiting toxicity. In this study, cutaneous toxicity
was mild, as was mucositis. Side effects were
generally less severe than with infusional ECF,
with similar levels of myelosuppression necessitating
dose reductions and delayed courses of treatment.
This infusional FAC regimen does not appear to
offer a significant improvement in side-effect profile
over conventional regimens, inparticular over the
combination of infusional ECarboF or 5-FU with
weekly doxorubicin [12,14].
What is the future for infusional 5-FU? Although
we could have escalated the drug dose further, single-
agent studies have not proved a dose-related effect
beyond 150 mg/m2 [4], Infusional 5-FU as part of
ECF and ECarboF is undoubtedly very active,
although it is not clear if the prolonged infusion
contributes beyond bolus administration. Moreover,
single-agent studies have shown tumour response in
bolus 5-FU refractory tumours [4], The future for
prolonged fluoropyrimidine therapy probably lies in
the new generation of oral drugs. Capecitabine is a
fluoropyrimidine carbamate given orally that may be
targeted to tumour cells by differential expression of
the enzyme involved in its activation (personal
communication M. Mackean [15]). UFT comprises
Tegafur, another fluoropyrimidine, and the dihydro-
pyrimidine dehydrogenase inhibitor Uracil [16]. Both
these compounds are active and may replace
infusional 5-FU because of better tolerability.
In conclusion, infusional FAC, although safe and
effective, does not seem likely to offer any
advantages over existing regimens. The response
rates for primary and metastatic disease of 71% and
61% did not meet our minimum criteria for
proceeding to a larger trial. Given the cost and
intensity of labour required to maintain Hickman
lines, we did not pursue this combination further.
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